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 ABSTRACT 
TRAIL is a member of TNF superfamily and binding of TRAIL to its receptors 
induces cell death with apparent specificity for carcinoma cells compared with 
normal epithelium. On this basis, a number of TRAIL-targeted therapies are 
currently under investigation as anti-cancer agents. Recent studies in our lab 
have shown that membrane bound forms of both FasL and CD40L are more 
potent in cell death induction, suggesting that a membrane bound TRAIL could 
be more effective in cell death induction compared to the wild-type or the 
soluble counterparts. TRAIL gene therapies have demonstrated that ex vivo 
infection of cancer cells with a recombinant adenovirus expressing TRAIL 
(RAdTRAIL) enhances apoptosis and promotes tumour regression. In the 
present study, we have generated two adenoviral vectors. The first one 
expressing wild-type TRAIL (RAd wtTRAIL) that subject to cleavage from cell 
membrane and the second adenoviral vector expressing fusion CD40LTRAIL 
protein that is resistant to metalloproteinase cleavage (RAd CD40LTRAIL). The 
direct effects of these viruses were examined on TRAIL receptor positive 
carcinomas either alone or in combination with different chemotherapeutic 
drug. The RAd CD40LTRAIL that expressed the membrane bound 
CD40LTRAIL was found to exhibit more cell death than the RAd wtTRAIL. 
This cell death was through the activation of caspase 3/7. 
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1.1 : Cancer and its clinical management. 
1.1.1 : The hallmarks of cancer. 
Cancer is fundamentally a genetic disease developing from mutations in genes 
encoding for proteins important for normal cell proliferation, differentiation 
and homeostasis, resulting in defects in the regulatory mechanism governing 
these processes. Most cancer developed by Deoxyribonucleic acid (DNA) 
damage that regulates normal cell homeostasis. Tumour suppressor genes and 
oncogenes are common targeted groups susceptible to genetic lesion. Mutations 
which occur  in tumour suppressor genes results in total loss or down-
regulation in functional proteins, whereas mutation that occurs  in oncogene 
results in dominant gain of function in proteins which are required for normal 
cellular functions (Hahn et al., 1999). Although there are more than 200 
different types of human cancers, it has been proposed that normal cells 
regardless of anatomical location or aetiology require six alterations in cell 
physiology in order to induce malignant growth. This includes self-sufficiency 
from growth factor signals, insensitivity to anti-growth signals, evasion of 
apoptosis, limitless replicative potential, angiogenesis within the tumour mass 
and tissue invasion/metastasis (Hanahan and Weinberg, 2000). Recently four 
new hallmarks of cancer have been proposed which including abnormal energy 
metabolism, evading immune system, genome instability and inflammation 
(Hanahan and Weinberg, 2011). These “hallmarks of cancer” enable a single cell 
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to grow into a tumour mass which is independent of its local environmental 
cues and self-sufficient for nutrient delivery.  
Tumour Microenvironment is the cellular environment within the tumours, 
including carcinoma associated fibroblasts, immune cells, surrounding blood 
and lymphatic vascular endothelial cells. Recent studies demonstrate a positive 
correlation between the present of the inflammatory cells and tumour 
progression (Coussens and Werb, 2002). Hepatic tumours have been associated 
with chronic inflammation: for example, Hepatitis B and C (Karin et al. 2006). 
Chronic inflammations create a local microenvironment for tumour progression 
through the interactions of tumour cells and inflammatory cells. In excessive 
tumour cell proliferation hypoxia and necrosis stimulate tumour cells and 
tumour microenvironment cells to release number of growth factor and 
chemoattractive for monocytes and macrophages (Allavena et al., 2008). In turn, 
recruited monocytes and macrophages secrete Vascular Endothelial Growth 
Factor Receptors (VEGF), Fibroblast growth factors (FGF), Hepatocyte growth 
factors (HGF) and chemokines such as CXC12 and IL-8 within the tumour 
microenvironment and stimulate tumour cell proliferation, survival and 
angiogenesis (Lorusso and Ruegg, 2008). 
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1.1.2 : Cancer treatment. 
1.1.2.1 : Current therapeutic regimes. 
The three main approaches for cancer treatment are surgical excision, 
irradiation and chemotherapy, with the preferred choice of regimen depending 
on the tumour type and stage of disease. Surgical removal and radiotherapy 
treatment are generally the first line of treatment for localised cancer and can be 
curative in appropriately selected patients. Chemotherapy may be used 
palliatively to improve symptoms and prolong survival of cancer patients, or as 
an adjuvant to surgery or radiotherapy to reduce the risk of recurrent growth. 
Indeed, combination treatments with chemotherapy and radical surgery or 
radiotherapy in clinical trials have clearly demonstrate improvement in 
survival compared to surgery or radiotherapy alone for a number of common 
cancers, including breast, colorectal, lung, and pancreatic cancers. Combination 
chemotherapy can effectively afford cure for certain cancers such as germ cell 
tumours, Hodgkin’s disease and Non-Hodgkin’s Lymphoma even in the 
presence of disseminated disease. However, for the most common carcinomas 
chemotherapy is generally palliative in the setting of advanced disease and 
benefits must be weighed against potential toxicity of drugs with relatively 
non-specific mechanisms of action. The most common anti-cancer drugs used 
currently have been identified more than 50 years ago by in vitro cell line 
screening programmes. These anti-cancer drugs exhibit different mechanisms of 
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action and side effects. In general anti-cancer drugs function through interfering 
with the cell cycle and cell division, particularly at the level of DNA synthesis 
and replication. For example, Cis-platin forms cross-linking covalent bonds 
with DNA and thus impedes DNA replication and enhances apoptosis. 5-
fluorouracil is a pyrimidine analogue and thus prevents thymidine synthesis. 
Doxorubicin and etoposide stabilise the topoisomerase II/DNA complex and 
thus effectively seize up DNA synthesis (Rang et al., 1995). All these 
compounds have been extremely useful for cancer treatments, although they 
have potential severe toxic side effects. However the efficacy of these 
chemotherapeutic drugs can be significantly reduced due to the genetic 
alteration resulting in promoting drug resistance. For example, relative 
unresponsive chemotherapy is associated with tumours bearing mutations in 
the tumour suppressor protein p53 as a result of function loss (Aas et al., 1996, 
Hait and Yang, 2006). In addition, acquiring drug resistance after a period of 
treatment is another challenge as with ovarian carcinoma culminating in 
disease relapse or progression (Khaider et al., 2012) Given the clinical 
limitations of conventional chemotherapy, the search for novel therapeutic 
agents is of paramount importance. 
 
Chapter 1                                                                                                         Introduction 
6 
1.1.2.2 : Novel mechanisms of cancer therapy. 
Understanding of the mechanisms of tumourigenesis has facilitated the 
development of selective anti-cancer therapies and reduced the side effect that 
often exhibited by traditional chemotherapeutic drugs. For example, inhibition 
of angiogenesis by preventing tumour vascularisation is a recent approach for 
controlling tumourgenisis where inhibition of the angiogenic growth factor 
receptors such as Fetal liver kinase 1 (Flk-1/KDR), VEGFR and PDGFR, induced 
rapid microvasculature cell death and tumour regression (Laird et al., 2002, 
Burris et al., 2004). Targeting normal endothelial cells would overcome the 
problem of drug resistance because these cells are genetically stable (Kerbel, 
2008). Angiogenic inhibitors drug would suit different tumour types for 
example Avastin (bevacizumab) (Ferrara et al, 2005). In addition, angiogenesis 
inhibitor could have side effect such as bleeding, clots, and hypertension 
(Kristina and William 2010). Furthermore, recent studies show that tumours can 
develop resistance to angiogenic inhibitors through alternative angiogenesis 
pathway Such as FGF-2 (Casanovas et al., 2005). A number of recent angiogenic 
inhibitors used in combination with conventional cytotoxic drugs in clinical 
trial have now been demonstrated to improve survival (de Bouard et al., 2007, 
Mackey et al., 2012). Moreover, better understanding of the mechanism of 
kinases whose dysfunction is critical for the maintenance of the cancer cell 
phenotype has lead to development of a number of kinase inhibitors. For 
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example, the anti-cancer agents Imatinib (Gleevec, STI-571), and Lapatinib have 
received approval from the US Food and Drug Administration (FDA). Imatinib 
has proved extremely successful for the treatment of Bcr-Abl positive chronic 
myeloid leukaemia, and c-kit positive Gastrointestinal stromal tumours by 
specifically inhibiting these hyper-active kinases (O'Dwyer and Druker, 2001). 
Likewise, the kinase signalling activity, most commonly of VEGFR, in tumour 
endothelium can be targeted for inhibition of angiogenesis.  
Immunotherapy is also a potential strategy for cancer treatment, where better 
understanding of tumour immune-environment has lead to the development of 
specific monoclonal antibodies capable of binding key targets. Monoclonal 
antibodies can trigger specific immune-response to attack cancer cells or to 
block specific dysfunctional receptors in cancer cells. For example, about 30% of 
breast carcinomas acquire gene amplification of the epidermal growth factor 
receptor (EGFR) family member Her-2/neu (ErbB-2) receptor promoting 
constitutive dimerisation and activation of ErbB family members (Slamon et al., 
1987). The development of trastuzumab (Herceptin), an antagonistic 
monoclonal antibody directed towards Her-2/neu, used in conjunction with 
chemotherapy has significantly increased the survival rate of patients with Her-
2/neu positive breast carcinomas compared to chemotherapy alone (Slamon et 
al., 2001, Lower et al., 2009).  
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Furthermore, triggering the Immune system also has demonstrated some 
clinical activity in those tumours associated with an inflammatory or immune 
response, such as melanoma, renal cell carcinoma and hepatocellular 
carcinoma. Most cancers have the potential to be a target for 
immunotherapeutic manipulation. For example, at the tumour site there is a 
concurrent recruitment and infiltration of lymphocytes which suggest potential 
cytotoxic effector cell activation. In addition, tumour-infiltrating lymphocytes 
(TIL) expanded ex vivo in the presence of interleukin-2 (IL-2) display anti-
tumour cytolytic activity. However, TIL are frequently only partially activated, 
proliferate only at very low level and fail to kill tumour cells unless activated by 
IL-2 in vitro suggesting that immunosuppressive mechanisms prevent T cell 
maturation into useful anti-tumour effectors.  The activation of tumour-specific 
cytotoxic T cells requires three synergistic signals: the presentation of tumour 
antigen by antigen-presenting cells to specific T-helper cells; the interaction 
between co-stimulatory factors (e.g. CD40 and its ligand); and the secretion of 
immunostimulatory cytokines (e.g. IL-2, IL-12) from activated dendritic cells 
(DCs). Dendritic cells (DC) are the most potent professional antigen-presenting 
cells that can capture, process and present antigens to naïve T cells, stimulating 
their proliferation and activation. They provide the optimum co-stimulatory 
environment, to evoke an immunostimulatory signal and key to this process is 
ligation of the CD40 receptor on DC by its ligand expressed by T-helper cells. 
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The direct anti-tumour effects of CD40L ligation have been observed from 
clinical experiment. Treatment of Burkitt lymphoma and Multiple myeloma 
with CD40L result in marked decrease in tumour proliferation (Teoh et al, 
2000). In addition to the direct anti-proliferative effect of the CD40 ligation in 
carcinoma, CD40L involve in immune recognition and generation of cytotoxic T 
lymphocyte cell. The cytotoxic effects are mediated by the interaction of CD40 
expressed on the DCs with CD40L expressed on antigen presenting cells (Van 
Mierlo et al, 2002). CD40-mediated stimulation of DCs and provides help 
required by CD8+ CTLs, which target tumour cells independently of their CD40 
status. Moreover, delivery of CD40L by recombinant adenovirus (RAd-CD40L) 
to tumour was sufficient to stimulate anti-tumour response depend on CD8+ 
and CTLs (Eliopoulos and Young et al, 2004). 
Furthermore, cytokines and immunotherapy might be a potential strategy as 
they directly induce tumour cell death. Indeed, the first systemic therapy for 
cancer, Coley’s toxins relied on the production of endogenous TNF for its 
tumour cytotoxicity, reviewed by (Old, 1985). Large numbers of animal studies 
have demonstrated cytokines multiple effects within an organism which can 
potentially contribute to the regression of tumours. In addition cytokines can 
enhance or initiate a host immune response to the tumour cell by activating 
cytotoxic T lymphocytes and NK cells (Zamarron and Chen, 2011). 
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1.2 : The TNF superfamily of receptors and ligands. 
1.2.1 : The TNF ligand family. 
The tumour necrosis factor (TNF) superfamily of cytokines  plays an essential 
role in immune responses and inflammation by modulating lymphocyte 
proliferation and apoptosis which is implicated in maintaining homeostasis and 
self tolerance (Cancro and Smith, 2003). TNF, was first identified in 1975 
(Carswell et al., 1975) and consequently with the cloning of human TNF 
(Pennica et al., 1984), and with the large-scale screening of “expressed sequence 
tags” (ESTs), it is now known that TNF belongs to a large family of proteins (the 
TNF superfamily) which mediate cellular effects by activating receptors (the 
TNF-R superfamily) directly coupled to signalling pathways. To date TNF 
family ligands include 19 identified members, all of them are Type II 
transmembrane proteins that have an intracellular N-terminus and an 
extracellular C-terminus except Lymphotoxin alpha (LTα) and Vascular 
Endothelial Growth Inhibitor (VEGI).Sequence analysis of TNF ligands 
indicates that only 25-30% of homology between members exists despite the 
fact that all members possess the characteristic TNF-homology domain (THD), 
a conserved sequence of 150 amino acids located at the C-terminal of the 
extracellular domain. The THD is the biologically active domain of TNF 
ligands, and consists of a conserved chain of aromatic and hydrophobic 
residues folding into a β sandwich with “jellyroll” topology. Analysis of 
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crystals purified from recombinant TNF ligands has confirmed the trimeric 
formation of recombinant TNF ligands (Pennica et al., 1984, Banner et al., 1993). 
TNF ligands are biologically active as self assembling, non covalent bound 
trimers (Peschon et al., 1998), expressed at the cell  membrane as membrane 
attached molecules; however some ligands are subject to extracellular 
proteolytical cleavage from membrane by the action of specific group of 
proteases belonging to the family of metalloproteases (MMPs) to produce 
soluble TNF ligand molecules. Other TNF ligands, such as LT, are expressed 
only as soluble molecules but may also be recruited to the cell membrane to 
form heterotrimeric membrane anchored complexes (Idriss and Naismith, 
2000). With the exception of soluble TNF ligands, which appears to mediate a 
far more potent cytotoxic effect than its membrane bound form (Mohler et al., 
1994), most TNF ligands are biologically less active as a soluble cytokine 
(Schneider et al., 1998). 
1.2.2 : The TNF receptor family. 
Twenty-nine members of the TNF-receptor family have been identified so far 
(Table 1.1). The majority of these proteins are Type I transmembrane proteins 
which are characterized by extracellular N-terminus, intracellular C-terminus, 
with the exception of the recently identified members BCMA, TAC1, BAFF-R 
and XEDAR which are Type III transmembrane proteins which lack a signal 
peptide. Sequence analysis of the TNF receptors has revealed a sequence 
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homology of 20-25% between TNF receptor members. However, a characteristic 
cysteine-rich domain (CRD) exists between the TNF receptors. These 
pseudorepeats are defined by interchain disulphide bonds generated by highly 
conserved cysteine residues within the receptor chains (Smith et al., 1994). TNF 
receptors can be categorized into 4 categories based on structural similarities 
(Table 1.1). The first group, which include Fas, TNF-RI, TRAIL-R1 and TRAIL-
R2 belong to the death domain receptors and are defined by a highly 
homologous region of approximately 80 amino acids within the cytoplasmic 
domain of the receptor and are termed as Death Domain (DD). Death receptors 
are the only members of the TNF receptor superfamily that can directly induce 
cell death. The second group consists of decoy receptors that are incapable of 
activating signalling pathways but can bind ligand with equal affinity and 
therefore can possess indirect inhibitory effect on the activation of functional 
receptors by binding to active ligand. TRAIL-R3 and TRAIL-R4 are membrane 
attached molecules that lack key domains within the cytoplasmic tail that are 
responsible for signal transduction. In contrast the TNF receptors DcR3 which 
binds FasL, and osteoprotegerin (OPG) which binds TRANCE, lack the 
transmembrane regions and thus function as soluble receptors. The third group 
of TNF receptors contains the atypical Type III proteins whilst the last group 
are functional Type I proteins that lack a DD, and includes CD40, CD30, 
TRANCE and TNF-R2. 
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Table1. 1: The TNF superfamily of ligands and receptors 
Death Domain Receptors Cognate ligand 
TNF-R1 TNFα/LT-β 
Fas FasL 
TRAIL-R1 TRAIL-L 
TRAIL-R2 TRAIL-L 
TRAMP TWEAK 
DR6 UN 
NGFR NGF 
EDAR EDA-A2 
 
Decoy Receptors Cognate ligand 
TRAIL-R3 TRAIL-L 
TRAIL-R4 TRAIL-L 
OPG TRANCE-L 
DcR3 FasL 
 
Other Receptors Cognate ligand 
   CD40 CD40L 
TRANCE TRANCE-L 
TNF-R2 TNFα/LT-β 
LT-βR LTα1β2/LIGHT 
CD30 CD30L 
CD27 CD70 
4-1BB 4-1BBL 
OX40 OX40L 
Fn14 TWEAK 
HVEM LTα/LIGHT 
TROY UN 
GITR GITR-L 
RELT UN 
 
Type III receptors Cognate ligand 
BCMA APRIL/BAFF 
TAC1 APRIL/BAFF 
BAFF-R EDA-A1 
XEDAR EDA-A2 
 
UN = unidentified ligand 
adapted from (Bodmer et al., 2002). 
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1.2.3 : TNF receptor-ligand interactions. 
The fact that the TNF receptors lack any intrinsic kinase activity highlights the 
importance of interaction with their ligands for signal transduction, prior to 
TNF receptor ligand interaction, trimer structures of most TNF ligands and 
receptors are required. This 3:3 stoichiometry has been confirmed by analysis of 
the crystal structures of TRAIL bound to TRAIL-R2 (Hymowitz et al., 1999). 
Membrane attached receptors have been thought to exist as a monomeric 
structures and that a trimeric ligand binds three units of the receptor, however 
recent results suggest that some members of the TNF receptors (FAS, TNFRI, 
TNFRII) preassemble on the cell membrane prior to ligand binding (Chan et al., 
2000). The TNF receptor preassembled complex formation on the surface 
requires the N-terminal domain including parts of the first CRD, termed as pre-
ligand binding assembly domain (PLAD), this was confirmed by transplanting 
the PLAD of the TNFRI onto TNFRII which results in the assembly of 
heterotrimeric receptor complex.  However, not all of the receptors seem to be 
pre-assembled into trimers prior ligation, as stimulation of cells with TNF 
ligand significantly enhanced receptor trimer formation (Chan et al., 2000). 
Therefore, ligation is still critical for receptor trimerisation.  
.  
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1.3 : Apoptosis. 
1.3.1 : Introduction. 
Apoptosis is a programmed cell death which is a morphologically and 
biochemically different form of cell death from necrosis. Apoptosis is 
characterised by condensation and fragmentation of DNA, nuclear degradation, 
cell shrinkage, membrane blebbing, a decrease in mitochondrial membrane 
potential and the exposure of phoshatidylserine on the outer leaflet of the 
plasma membrane (Kerr et al., 1972). Apoptosis is a highly controlled process 
involved in development as in embryo and tissue homeostasis, and to remove 
unwanted or defective cells from the body without inducing inflammatory 
responses. Moreover, apoptosis deregulation is involved in various diseases, 
including cancer, autoimmunity and degenerative disorders. Early genetic 
studies on the nematode C. elegans identified the mechanisms of apoptosis which 
found that apoptosis is genetically controlled by different initiators, effectors 
and inhibitors.  
 
1.3.2 : The caspase family of cysteine proteases. 
The apoptotic pathway is directly induced and regulated by a group of 
aspartate-directed cysteine proteases known as caspases. Caspases are highly 
homologous to the Caenorhabditis elegans death gene ced-3 and are expressed as 
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inactive zymogens, in order to control their biological activity (Alnemri et al., 
1996) reviewed in (Henkart, 1996).  
At least 14 mammalian caspases have been identified so far (Fan et al., 2005). 
Caspases can be classified into activators, effectors and inflammatory inhibitors 
(Table 1.2), which cleave and activate each other to create amplifiable cascades 
of proteolysis (Boatright and Salvesen, 2003). Activator caspases including 
caspase-8, caspase-9, and caspase-10, are synthesized as inactive zymogens, 
therefore called procaspases which contain motifs that interact with adaptor 
proteins or undergo self-association, a process which is required for their 
autocatalytic cleavage into an active form. Activator caspases induce the 
proteolytic processing of downstream effector caspases or the executioner 
caspases which include caspase-3, caspase-6 and caspase-7. Effector caspases 
target several key components critical for cell viability including components of 
cellular DNA repair machinery such as poly ADP-ribose polymerase (PARP) 
and DNA-PK (Lazebnik et al., 1994, Casciola-Rosen et al., 1995, Nicholson et al., 
1995), structural proteins such as actin, fodrin, lamin and gelsolin, which are 
important for intact nuclear and cellular morphology (Cryns et al., 1996, Orth et 
al., 1996, Takahashi et al., 1996, Kothakota et al., 1997, Mashima et al., 1997)  
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Table 1.2: The Subfamily members of caspase family. 
 
Subfamily Role Member 
I Apoptosis activator 
(Initiator) 
Caspase-2 
Caspase-8 
Caspase-9 
Caspase-10 
II Apoptosis executioner 
(Effector) 
Caspase-3 
Caspase-6 
Caspase-7 
III Inflammatory mediator Caspase-1 
Caspase-4 
Caspase-5 
Caspase-11 
Caspase-12 
Caspase-13 
Caspase-14 
 
(Fan et al., 2005)  
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1.3.3 : Pathways initiating apoptosis. 
Two distinct pathways can trigger apoptosis mainly through the caspase family 
proteases. The first pathway involves the activation of caspases via cell surface 
receptor (death receptor). This pathway requires the recruitment of pro-caspase 
8 or 10 into the cytoplasmic domain of the receptor and formation of a complex 
that results in auto catalytic activation of the pro-caspases to the active caspases. 
Second route which leads to initiating apoptosis is the more conserved pathway 
which is activated by either intra or extra stresses for example γ-radiation, 
chemical and cytotoxic drugs, this pathway leads to DNA damage followed by 
intracellular changes resulting in mitochondrial membrane  potential loss and 
release of cytochrome c and subsequent activation of caspase-9. Both pathways 
directly lead to processing and activating downstream effector caspases. 
 
1.3.3.1 : Mechanism and regulation of mitochondrial-mediated apoptosis. 
Mitochondrial-mediated apoptosis involves a sequence of process that mainly 
rely on the release of a number of pro-apoptotic proteins into the cytosol, some 
of these proteins induce caspase activation (e.g. cytochrome c) and others cause 
caspase-independent cell destruction (e.g. apoptosis-inducing factor and 
endonuclease G). The release of these proteins is mainly dependent on the   
integrity of mitochondrial membrane, that could be impaired by intra or extra 
stresses leading to a mitochondrial outer-membrane permeabilization (MOMP), 
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a process that results in release of cell-death-inducing mitochondrial molecules 
and uncoupling of oxidative phosphorylation and production of toxic free 
radicals as a result of diversion of electrons from the respiratory chain. MOMP 
induced-cell death is mainly characterised by necrosis (Green and Kroemer, 
2004, Spierings et al., 2005), a process whereby cells swell and eventually 
rupture. Several proteins have been reported to regulate the MOMP process, 
central to these regulators are members of the Bcl-2 family proteins, a large 
family that consists of at least of 26 members in humans of both pro-survival 
and apoptotic–inducing proteins which either induce or inhibit MOMP (Cory et 
al., 2003, Reed et al., 2004). Bcl-2-like family members which include Bcl-2, Bcl-
xL, Bcl-w, A1 and Mcl-1 are considered to be pro-survival regulators, whereas 
cell death is controlled by two Bcl-2 groups of proteins, the Bax and BH3-only 
families.  
The Bax-like proteins are cell death inducers. These include Bax, Bak and Bok. 
Bax and Bak and are thought to directly trigger the cytochrome c release from 
mitochondria to cytosol, a process which are controlled by both the Bcl-2 family 
pro-survival and the pro-apoptotic BH3-only proteins (Cory and Adams, 2005).  
In healthy cells Bax exists in cytosol as an inactive monomer and upon 
apoptotic stimuli Bax translocates to mitochondria and oligomerises. In 
contrast, Bak forms an oligomerised mitochondrial membrane structure even in 
healthy cells and requires additional conformation changes to become pro-
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apoptotic. The BH3-only pro-apoptotic family, which consists of Bad, Bid, Noxa 
and Bim are damage sensors that function by direct inhibition of the Bcl-2 pro-
survival proteins via heterodimerising to and locking the survival protein into 
dysfunctional configuration. This binding  is highly selective and varies widely 
in affinity (Chen et al., 2005, Certo et al., 2006, Kim et al., 2006), where Bim and 
Bid bind to and block all the pro-survival proteins, Bad is more selective as it 
binds only to Bcl-2, Bcl-xL and Bcl-w, whilst Noxa binds to Mcl-1 and A1 (Chen 
et al., 2005). Mitochondrial dysfunctional proteins have been reported during 
tumourigenesis, in human gastric and colorectal cancers loss of function 
mutations in Bax and Bak have been detected (Rampino et al., 1997, Kondo et 
al., 2000). In contrast, Bcl-2 is over-expressed in cis-platin-resistant ovarian 
carcinoma cell lines (Eliopoulos et al., 1995).   
The role of anti-apoptotic Bcl-2 proteins in preventing caspase activation has 
been reported. However, the mechanism is not fully understood. Given that 
Bcl-2 does not directly interact with Apaf-1 (Moriishi et al., 1999) Bcl-2-like 
proteins may function by maintaining mitochondrial membrane integrity and 
thus preventing the release of cytochrome c, a molecule that is required for 
Caspase 9 activation. One hypothesis suggests that Bax/Bcl-2 heterodimer 
complex may prevent Bcl-2-like proteins from maintaining pre-existing 
channels within the mitochondrial membrane in a closed configuration (Narita 
et al., 1998, Shimizu et al., 1999), such a scenario would lead to subsequent 
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change in mitochondrial membrane potential, matrix swelling and 
mitochondrial rupturing enabling the release of cytochrome c (Vander Heiden 
et al., 1997). This seems unlikely as apoptosis could occur even in the absence of 
mitochondrial rupture, given that mitochondrial depolarisation occurs 
downstream of cytochrome c release (Bossy-Wetzel et al., 1998). 
1.3.3.2 : Receptor-mediated apoptosis. 
Receptor-mediated apoptosis is largely attributed to the death receptors of the 
TNF receptor superfamily (Table 1.1) via the death domain (DD), which is 
required for caspase-8 processing and transduction of the apoptotic signals 
(Peter and Krammer, 2003). Mutations in DD of Fas has been reported to cause 
lymphoproliferation disorder in mice that is manifested by accumulation of 
unwanted lymphoid cells as a result of a defect in Fas-mediated apoptosis 
(Watanabe-Fukunaga et al., 1992). The DD functions by binding to other DD 
containing-adaptor proteins such as FADD, TRADD and RIP enabling signal 
transduction and apoptosis. Indeed, ectopic expression of proteins that contain 
DD alone can initiates cell death (Chinnaiyan et al., 1995). In addition to the DD, 
FADD importantly possesses a death effector domain (DED) which allow direct 
recruitment of pro-caspase-8 to the receptor complex (Chinnaiyan et al., 1995). 
The sequence of events leading to caspase-8 activation is well examined for Fas 
and TNF-induced apoptosis (Figure 1.1). Ligation of Fas receptor with Fas 
ligand (FasL) results in higher-order of aggregation of the receptor molecules 
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and the recruitment of FADD to the Fas cytoplasmic domain via DD-DD 
interactions (Holler et al., 2003). Upon binding of FADD to the DD of the 
cytoplasmic tail of Fas, pro-caspases-8 and -10 are then recruited to FADD via 
the interaction with the FADD death effector domain (DED) to form what is 
called death-receptor induced signalling complex (DISC)  (Sprick et al., 2002). 
DISC is usually formed within seconds of Fas ligation (Peter and Krammer, 
2003). As a result of effective formation of the DISC autocatalytic activity of pro-
caspases-8 and -10 is initiated resulting in formation of the corresponding active 
caspases (Sprick et al., 2002). However, it is still unclear whether caspase-10 can 
trigger cell death in the absence of caspase-8 (Lavrik et al., 2005), where Fas-
mediated cell death requires formation of a single effective complex, TNF-R1 
stimulation leads to formation of two signalling complexes. Complex I which 
consists of the TNFR1, TNF, TRADD, RIP, TRAF-1/2, and probably other 
molecules which trigger the NF-ĸB-dependent survival signals. Once this 
signalling complex is unable to induce survival signals via NF-кB pathway, 
FADD, pro-caspase-8 and-10 and FLIPL are recruited to form the so-called 
traddosome or complex II which results in activation downstream death 
signalling pathway (Micheau and Tschopp, 2003). The choice between survival 
and death relies on the efficiency of the complex II formation, caspase-8 
activation and the level of FLIP in the cells that blocks the procaspase-8 
activation. 
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1.3.4 : Cross talk between death receptor and mitochondrial-mediated 
apoptotic pathways. 
Previously it was thought that mitochondrial-mediated cell death and receptor-
induced cell death were two distinct pathways. However, with caspase-3 being 
activated in the two pathways suggest that a cross talk between the two 
pathways is possible. Fas-mediated apoptosis can occur by two distinct 
biochemical pathways, thus classifying cells as Type I or Type II responsive. In 
type I cells death receptor are involved, and as a result of recruitment of large 
quantities of caspase-8 into the DISC, caspase-3 is rapidly activated which 
precedes the loss of mitochondrial membrane potential. In Type II responsive 
cells, the level of DISC formation is dramatically reduced and caspase-3 is 
activated as a result of loss in mitochondrial membrane potential, and a 
subsequent mitochondria-induced apoptotic signals rather than direct 
activation of caspase-8. Whilst c-FLIP can  inhibit both pathways by interfering 
with the DISC complex (Scaffidi et al., 1998, Scaffidi et al., 1999), Bcl-2 family 
members such as Bcl-2 and Bcl-XL can only block type II signalling (Willis et al., 
2003). Despite the reduced levels of DISC formation in Type II cells, the small 
proportion of active caspase-8 produced can induce the cleavage of Bid, cleaved 
Bid can bind to Bax at the mitochondria and induce a conformational change in 
Bax enabling the release of cytochrome C (Desagher et al., 1999).  
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Figure 1.1: Schematic representation of receptor proximal events in death 
receptor-induced apoptosis. 
Trimeric Fas receptor binds FADD enabling direct recruitment and processing 
of pro-caspase 8. Trimeric TNF-RI directly binds TRADD, but due to the lack of 
a death effector domain (DED) within TRADD, binds FADD to promotes pro-
caspase 8 interactions. TRADD also binds RIP, which via TRAF2 interactions 
promotes NF-ĸB signal transduction. C-FLIP inhibits death receptor apoptosis 
by interfering with the processing of pro-caspase-8. DD; death domain. 
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1.4 : Structural and functional aspects of TRAILRs-TRAIL 
interactions. 
1.4.1 : TRAIL. 
Tumour necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL) is also 
known as Apo2L or (CD253). TRAIL was first reported in 1996 as a novel 
protein that possessed a sequence homologous to the extracellular domain 
CD95 ligand (Fas-L) and TNF ligand (Pitti et al., 1996, Wiley et al., 1995). 
Human TRAIL is a Type II transmembrane protein of 281 amino acids (aa), 
consisting of a 17 amino acid cytoplasmic domain, a 21 amino acid 
transmembrane domain, and a 243 amino acid extracellular domain. 
Recombinant human soluble TRAIL/Apo2L is a 168 amino acid polypeptide 
spanning the sequence from 114-281 aa of the extracellular domain. It forms the 
active region of TRAIL that can bind TRAIL receptors and initiate signalling. 
Like most of the TNF ligand members, TRAIL is naturally expressed at the cell 
surface as homotrimeric molecules then naturally cleaved into soluble form by 
the action of specific proteases belong of the metalloproteansaes (MPs). 
Crystallographic ananlysis of TRAIL has revealed a high similarity with the 
crystal structure of TNF ligand and CD40L (Wiley et al., 1995). 
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1.4.2 : The TRAIL receptors. 
Five human TRAIL receptors have been reported so far, including TRAIL-R1 
(DR4), TRAIL-R2 (DR5), TRAIL-R3 (DR1), TRAIL-R4 (DcR2) and the fifth 
receptor reported for TRAIL is OPG, a soluble member of the TNF receptor 
superfamily (Emery et al., 1998). TRAIL-R1 was the first TRAIL receptor cloned 
by using the death domain sequence of the TNF-R1 to search an EST database 
(Ashkenazi, 2002). Both TRAIL-R1 and R2 are type I transmembrane proteins, 
which contain an extracellular domain, a transmembrane domain, and a 
cytoplasmic domain. The cytoplasmic domain contains the death domain DD, 
therefore both TRAIL-R1 and R2 are called death receptors. TRAIL-R1 and R2 
shares a 58% sequence homology. TRAIL-R1 and R2 are capable of eliciting an 
apoptotic death response upon binding of TRAIL in a variety of carcinomas and 
primary tumour cells (Almasan and Ashkenazi, 2003). In addition to the ability 
TRAIL-R1 and R2 to induce cell death upon ligation with TRAIL, it has been 
reported that TRAIL-R1 and TRAIL-R2, as well as other members of the TNF 
receptor family containing DD may also be involved in non-apoptotic functions 
(Park et al., 2005). TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) lack the complete 
intracellular DD that is essential for signalling apoptosis and proposed to 
function as an antagonizing ‘‘decoy’’ receptors for the death domain containing 
TRAIL receptors (Degli-Esposti et al., 1997, Pan et al., 1997). TRAIL-R3 lacks the 
the complete intracellular domain and part of transmembrane domain. This 
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receptor is anchored to the membrane by Glycosylphosphatidylinosito (GPI) 
residue. Over expression of TRAIL-R3 can inhibit apoptosis in TRAIL sensitive 
cell (Kimberley & Screaton, 2004). TRAIL-R4 has truncated DD at the cytosolic 
part. Inhibition of apoptosis was observed with high expression of TRAIL-R4. 
Studies found overexpression of TRAIL-R4 can activate NF-ĸB (Degli-Esposti, 
1999). The fifth TRAIL receptor is OPG, which is a soluble member of the TNF 
receptor superfamily (Emery et al., 1998). OPG is involved in regulation of 
osteoclasts activation in the development and bone remodelling.  Like TRAIL-
R3 and R4, OPG function as a decoy receptor therefore it can bind to TRAIL and 
block the TRAIL-R1 and R2 induced apoptosis (Pritzker et al., 2004). 
. 
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Figure 1.2: TRAIL and its receptors. 
TRAIL is a homotrimeric ligand that binds to four closely related and 
chromosomally linked members of the TNFR superfamily. TRAIL-R1 and 
TRAIL-R2 which contain a cytoplasmic death domain and signal apoptosis; 
TRAIL-R3 is linked to the plasma membrane and lacks death domain; TRAIL-
R4 has a truncated, non-functional death domain. OPG, a soluble, more 
distantly related receptor, is capable of binding to Apo2L/TRAIL. 
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1.4.3 : Functional role of TRAILR-TRAIL interactions in normal cells. 
1.4.3.1 : TRAIL expressed in the lymphoid system. 
Like other members of TNF ligand involved in immune responses, TRAIL is 
widely expressed by a variety of immune-regulatory cells, TRAIL expression 
has been detected in activated and resting B lymphocytes, activated T cells, NK 
cells, monocytes, macrophages, and dendritic cells (Holoch and Griffith, 2009).  
The level of TRAIL expression is mainly determined by the proinflammatory 
cytokine profile, including Interferon (IFN)-γ which stimulate TRAIL 
expression (Griffith et al., 1999). It has also been reported that IL-2, IL-7, and IL-
15 induce the expression of TRAIL in NK cells and that LPS potentiates the 
cytotoxicity of macrophages and monocytes via TRAIL expression (Johnsen et 
al., 1999; Kayagaki et al., 1999: Halaas et al., 2000). 
The physiological role of TRAIL in the lymphoid system depends on the 
stimulation of immune cells. However, the precise function is still not fully 
clear. Recent animal studies found that TRAIL plays an essential role in viral 
infection as an activator molecule for natural killer cell-mediated cytotoxicity 
(Cretney et al., 2006). TRAIL also might be implicated in the regulation of 
haematopoiesis. Expression of TRAIL receptors on the hematopoietic 
progenitor cells (CD34+ cells) and mature erythroblasts is not detected therefore 
protected from TRAIL-induced apoptosis, while immature erythroblasts 
express TRAIL receptors and are sensitive to TRAIL (Sheridan et al., 1997, 
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Falschlehner et al., 2009). In addition, TRAIL plays an important role in 
mediating immune surveillance and tumour suppression. Collective studies on 
mice found that TRAIL can induce rejection or activate the apoptotic process in 
tumour cells whereas transplantation of TRAIL sensitive tumour into TRAIL-/- 
mice resulted in increased the size and the growth of the tumour and showed 
metastases to liver.  Other studies similarly show that TRAIL  knockout mice 
are more susceptible to initiate tumour and metastases (Holland, 2011). 
However, in other studies TRAIL receptor deficient mice showed enhanced 
tumour metastases without affecting primary tumour growth suggesting that 
this could be TRAIL specific function or a  mouse model specificity (Grosse-
Wilde et al., 2008).  
 
1.4.3.2 : TRAIL expressed in normal non-haematopoietic cells.  
While the expression of TRAIL on immune-regulatory cells is determined by 
the inflammatory cytokine profile, TRAIL expression has been detected on 
several human tissues including spleen, prostate and lung (Wiley et al., 1995, 
Pitti et al., 1996). Human hepatocytes express TRAIL as well as TRAIL-R1 and 
R2 which thought to play a critical role in regulation of hepatic cells and 
inflammation (Zheng et al., 2004). In addition, TRAIL is expressed in the central 
nervous system (CNS) at high level and plays critical role in induction of cell 
death after ischemic damage in neurons despite the expression of its four 
Chapter 1                                                                                                         Introduction 
31 
receptors (Daniels et al., 2005). Death receptors, TRAIL-R1 and R2, are also 
expressed widely in most of the same tissues as TRAIL. In contrast to TNF and 
Fas induced cell death, TRAIL is highly selective in cell death-induction and 
have low toxicity to normal cells (Wiley et al., 1995), This could be attributed to 
the preferential expression of the decoy receptors, TRAIL-R3 and R4, in normal 
cells, which might explain the resistance to TRAIL in normal tissues (Pan et al., 
1997, Sheridan et al., 1997). 
 
1.4.4 : Functional role of TRAIL in malignancies. 
1.4.4.1 : TRAIL expressed on lymphomas. 
The effect of TRAIL on lymphomas is highly dependent on the type of the 
haematological malignancy. In multiple myeloma (MM) cells TRAIL and 
TRAIL-R1/-R2 are highly expressed compared to normal B cell.  It was first 
reported by (Gazitt et al., 1999) that TRAIL is a potent inducer of apoptosis in 
MM, then followed by several studies that have indicated that ligation of highly 
expressed TRAIL and TRAIL-R1/-R2 may activate the autocrine apoptotic 
mechanism in melanoma cell line (Jourdan et al., 2009). However, studies on 
acute lymphoblastic leukaemia (ALL) were not fully explained the differential 
effect of TRAIL on TRAIL receptors which are expressed on ALL cells. Cellular 
sensitivity to TRAIL may be further regulated at the intercellular level as 
expression levels of c-FLIP correlates with TRAIL resistance in melanoma and 
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dendritic cells. In addition, TRAIL sensitivity was paralleled by changes in the 
c-FLIP expression level when cells were treated with actinomycin D or 
cycloheximide (Walczak et al., 2000; Griffith et al., 1998). However, the 
mechanisms of TRAIL sensitivity or resistance are still not fully clear. 
  
1.4.4.2 : TRAIL expression on carcinoma cells. 
Since the discovery of TRAIL and its receptors most of the studies have focused 
on the apoptotic effect of TRAIL on carcinoma cells whilst sparing normal cells. 
Numerous studies using carcinoma cell lines expressing TRAIL receptors and 
treated with rsTRAIL have confirmed that TRAIL induces growth inhibition or 
apoptosis of carcinomas originating from colon, lung, kidney, skin, breast, 
bladder and pancreas (Ashkenazi et al., 1999, Walczak et al., 1999). Further 
studies show that TRAIL and its receptors are expressed in normal colonic 
mucosa but the expression of TRAIL and its receptors was higher in adenomas 
and carcinomas. In ovarian carcinoma TRAIL mRNA is significantly higher 
than in normal human ovarian cells. Patients with high TRAIL expression have 
longer survival (Lancaster et al., 2003.). In addition, in human malignant breast 
cancer TRAIL expression is higher and can induces cell death and cancer cells 
are more sensitive to TRAIL than normal cells (Herrnring et al., 2000).   
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1.5 : Signalling by TRAIL. 
1.5.1 : Introduction. 
Following TRAIL interaction with TRAIL-R1 and R2 apoptotic adaptors 
proteins are recruited to the cytoplasmic tail of the TRAIL-R1 and R2, which 
results in initiating of a cascade of signalling mechanisms followed by apoptosis 
induction. However, binding of TRAIL to TRAIL-R3 and R4 or osteoprotegerin 
has a direct apoptotic inhibitory effect because they lack the ability to transduce 
apoptotic signals. 
 
1.5.2 : Mechanisms of apoptotic signal transduction by TRAIL. 
The interaction between TRAIL and its receptors TRAIL R1 andR2 is essential 
for TRAIL-induced apoptosis in carcinomas. Binding of homotrimeric TRAIL to 
TRAIL R1/R2 results in clustering and recruitment of the Fas Associated Death 
Domain adaptor protein (FADD) to TRAIL receptors. The death domain (DD) 
of FADD is directly interacting with DD of TRAIL-R1/R2. The FADD recruit 
procaspase-8 or 10 through second domain death-effector domains (DED) 
which interact with DED of procaspase-8 or 10 via homotypic interaction 
forming death-inducing signalling complex (DISC) (Kischkel et al., 2001). 
Recruited procaspase-8 or 10 to the DISC result in their activation and 
autocatalytic activity that result in activation of effector caspases (3, 6 and 7) 
and activation of apoptotic cell death (Figure:1.3). At this level cells can be 
Chapter 1                                                                                                         Introduction 
34 
divided into two deferent type according to the recruitment and sufficient 
activation of procaspase-8 or 10: type I cells in which DISC activation sufficient 
to induced cell death, and type II cells, In which DISC formation is not sufficient 
to trigger cell death through caspase-3 activation and which sequence 
additional signal amplification to induce cell death through the mitochondrial 
pathway. This connection between the extrinsic pathway and mitochondrial 
pathway is regulated through BH3-only protein Bid, which acts as a substrate 
for caspase-8. Activated caspase-8 at the DISC results in the cleavage of Bid into 
its truncated form tBid which translocates into the outer-mitochondrial 
membrane where it activates Bax and Bak. This leads to release of cytochrome c 
and proapoptotic factors from mitochondria and results in the recruitment and 
activation of caspase-9 which, like the DISC-activated caspases-8 and -10, 
activates the executioner caspases and induces cell death (Niemoeller and 
Belka, 2011). Inhibition of TRAIL apoptotic signalling can occur at several levels 
according to expression of apoptosis inhibitory protein. Studies by (Micheau et 
al., 2002) found that at the DISC level, the cellular FLICE inhibitory protein (c-
FLIP) bind FADD competing with the binding of caspase-8 and -10 resulting in 
inhibition of caspase activation. Studies found that C-FLIP has two different 
splice variants, c-FLIPL the long form and c-FLIPS the short form. The c-FLIPS 
recruited to the DISC site has the ability to inactivate caspase-8 and block 
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apoptotic signalling. However, the effect of c-FLIPL is not yet clear since it 
appears to be involved in both the apoptotic and a non-apoptotic signalling.  
In addition apoptotic signalling by TRAIL may be inhibited by the X 
chromosome-linked inhibitor of apoptosis (XIAP) which can bind to caspases-3, 
-7 and -9 inhibiting their induction of apoptosis that is required in type II cells. 
A protein called second mitochondrial activator of caspases/direct inhibitor of 
apoptosis-binding protein with low pI (Smac/DIABLO) is released from 
mitochondria during apoptosis inhibits the activation of XIAP (Maas et al., 
2010). Thus, TRAIL has the ability to induce apoptosis in tumour cells, that can 
be inhibited by several mechanisms at different level endogenously or by 
modulation of signalling pathway. 
 
1.5.3 : Mechanisms of non-apoptotic signal transduction by TRAIL. 
1.5.3.1 : The MAPK pathways. 
Mitogen-Activated Protein Kinase (MAPK) signalling cascades regulate a 
variety of physiological processes, ranging from cell differentiation, movement, 
proliferation and survival to apoptotic cell death and inflammatory responses. 
MAPKs can be activated by various stimuli such as growth factors, cytokines 
and hormones, or in response to environmental stress conditions such as 
irradiation, DNA damage, osmotic imbalance and heat shock. Higher 
organisms have three well-characterised subfamilies’ of MAPK. The 
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extracellular signalling-regulated kinase 1 and 2 (ERK1/2) function as regulators 
of cell growth, survival and differentiation, and inhibition of these kinases can 
be a target as anticancer treatment. The c-Jun N-terminal kinases (JNK) are 
essential for transcription and controlling programmed cell death as well as p38 
kinases which regulate the expression of different cytokines that are mainly 
activated by stress and environmental stimuli. 
The MAPK pathway is well organized and regulated by phosphorylation of 
substrate protein which functions as a switch to turn off or on the activity of 
protein. Thus, MAPKs provide a substrate for MAP Kinase kinase kinases 
(MAPKKKs) which sequentially phosphorylate and activate MAP kinase 
kinases (MAPKKs) which result in activation of kinase activity of the ERK, JNK 
or p38 (Tran et al., 2001). 
 
 
1.5.3.2 : The JNK MAPK pathway. 
JNK pathway is regulated by MAP Kinase Kinase (MKK) family proteins. The 
MKK4 and MKK7 are members of MKK family involved in the phosphorilation 
of JNK. Studies indicate that JNK activation is mediated through TRAF2 or RIP 
which activate MEKK1 that activate MKK4 (Hu et al., 1999). The molecular 
pathway of JNK activation by TRAIL is not fully understood and it could be 
activated through a secondary intercellular signalling complex (Varfolomeev et 
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al., 2005). The involvement of JNK activation induced by TRAIL  in cell death is 
still unclear  (Muhlenbeck et al., 1998). However recent studies found that 
TRAIL induced apoptosis requires the activation of JNK pathway (Corazza et 
al., 2006) suggesting that it could be a cell type dependent.  
 
1.5.3.3 : The ERK MAPK pathway. 
The extracellular signals which trigger the sequential protein kinases leading to 
activate the ERK pathway are well defined. Signals through activated receptors 
activate a significant number of well identified proteins such as Ras. The 
activation of Ras via the Raf Kinase family provoke the phosphorylation and 
activation of the MAPKKs MEK1 and MEK2. Thus activated MEK1/2 can 
phosphorylate ERK and induce its kinase activity. Also MEK1/2 can be 
phosphorylated through a Raf-independent pathway in which Ras binds to and 
activates the MAPKKK MEKK1(Lange-Carter and Johnson, 1994). Activation of 
the ERK pathway in general inhibits the effect of TRAIL-induced apoptosis. 
Studies on Jurkat T cells treated with ERK activators (TPA or OKT3) have found 
these to inhibit TRAIL-induced apoptosis via a mechanism that involves the 
inhibition of procaspase-8 cleavage and translocation of Bid (Soderstrom et al., 
2002). In addition, JNK and ERK translocate to the nucleus and activate c-Jun 
and c-Fos, which dimerize to activat the transcripton factor activator protein-1 
(AP-1). AP-1 complex composed of the Jun, Fos, ATF, and Maf protein families. 
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AP-1 is activated by several different agents. Activation occurs both 
transcriptionally and post-translationally, and signaling occurs predominantly 
through the mitogen-activated protein kinase cascade (Guseva et al., 2004). This 
AP-1 regulates the expression of multiple genes essential for cell proliferation, 
differentiation, and apoptosis (Li W et al., 2007).  
1.5.3.4 : The NF-ĸB pathway. 
The NF-ĸB family is a central regulator of immunity, development, apoptosis 
and cell proliferation. A variety of signals promote the induction and activation 
of NF-ĸB including inflammatory cytokines, bacterial and viral antigens, 
stresses such as γ-radiation, UV light and oxygen free radicals. NF-ĸB consists 
of  five family members in mammalian cells; c-Rel (Rel), p65 (RelA), RelB, NF-
ĸB1 (p105 and its processed oroduct p50) and NF-ĸB2 (p100 and its processed 
product p52). In unstimulated cells, NF-ĸB is founds in the cytoplasm as a 
functionally inactive complex which consists of NF-ĸB dimers sequestered by 
IĸB inhibitor proteins. The sequence of events of activation and release of NF-ĸB 
subunits from IĸBα occurs via the activation of the IKK signalosome (IĸB 
Kinase) which phosphorylates serines residues (Ser32 and Ser36) on IĸBα so that 
it is recognised and ubiqutinated by beta-transducin repeat containing protein 
(β-TrCP). This results in protesomal degradation of IĸBα and unmasking of 
nuclear localisation signal on the NF-ĸB dimer which can enter the nucleus as 
transcription factors and induce gene transduction. IKK is a large multiprotein 
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complex with a proximal molecular mass of 700-900 kDa and composed of 
many hetero-dimer proteins including IKKα (IKK1), IKKβ (IKK2) and IKKγ or 
termed NEMO. The catalytically active IKKα and IKKβ subunits dimerise and 
associate with at least two IKKγ subunits. IKKγ functions as a regulatory 
dimer, but is absolutely essential for IKK function and when a cell deficient in 
IKKγ it cannot induce IĸBα degradation and NF-ĸB/DNA binding (Yamaoka et 
al., 1998). IKKα is essential  for NF-ĸB2 processing and the regulation of a 
specific set of NF-ĸB responsive genes via the formation of p52/RelB 
heterodimers (Solan et al., 2002). In fact, the formation of specific NF-ĸB dimers 
occurs through two pathways. The first pathway, the canonical, involves the 
IKKα/IĸBα pathway resulting in the formation of predominantly p50/p65 
dimers, whereas the second non-canonical pathway which requires IKKα-
dependent processing of p100 NF-ĸB2 and the generation of p52/RelB 
heterodimers. A numbers of studies show that NF-ĸB can be activated by 
TRAIL (Jeremias et al., 1998) through ligation to R1,R2 and R4 (Degli-Esposti et 
al., 1997). Activated NF-ĸB by TRAIL involves the recruitment of RIP to the 
cytoplasmic domain of TRAIL-R1 and 2 by TRADD which results in further 
recruitment of other signalling molecules including TRAF2 that can activate the 
IKK complex (Devin et al., 2000). In addition, activated NF-ĸB can upregulate 
the expression of anti-apoptotic genes like cFLIP that results in inhibition of 
TRAIL-induced apoptosis (Gonzalvez and Ashkenazi, 2010). 
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Figure 1.3: Schematic diagram of TRAIL signalling pathway. 
TRAIL binding TRAIL R1 and TRAIL R2 and activated death receptors 
trimerize and recruit Fas-associated death domain (FADD) and recruit the 
initiator caspase-8/-10. This leads to activate procaspase -3,-6,-7 and 
subsequently activate caspase-3 and apoptosis. TRAIL can also trigger the 
intrinsic pathway through caspase-8-mediated cleavage of Bid. Cleaved Bid 
induces translocation of Bax into the mitochondria leading to release of 
cytochrome c activate caspase-9. This caspase 9 activates caspase-3 resulting in 
apoptosis. In addition c-JNK, NF-ĸB and ERK are activate by TRAIL involved 
the recruitment of RIP by TRADD. 
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1.6 : TRAIL-based therapy. 
1.6.1 : Introduction. 
The outcome from the administration of soluble recombinant TRAIL and 
monoclonal TRAIL-receptor antibodies in phase I and II clinical trails, and the 
observation that combination of TRAIL and chemotherapy induces a higher 
degree of carcinoma cell apoptosis than either agent alone, has highlighted the 
potential therapeutic role of TRAIL as a potent cancer treatment (Ashkenazi et 
al., 1999, Ashkenazi et al., 2008).  Targeting tumour cells by TRAIL to induce 
cell death and tumour regression can be achieved by two different strategies. 
The first strategy involves the use of viral gene therapy delivery systems to 
introduce the TRAIL gene into the cells. The second strategy involves the direct 
ligation of TRAIL via the systemic administration of recombinant soluble 
human TRAIL (rshTRAIL) or monoclonal TRAIL-receptor antibodies. Both of 
these strategies have the potential to induce tumour cytotoxicity directly via the 
up-regulation of apoptotic signalling. 
 
1.6.2 : Recombinant adenovirus TRAIL gene therapy. 
1.6.2.1 : Introduction. 
Gene therapy is a type of biological therapy for cancer. It was first defined as 
the deliberate introduction of genetic material into human somatic cells for 
therapeutic, prophylactic or diagnostic purposes (Gene Therapy Advisory 
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Committee). In the past 20 years gene therapy has progressed through to 
clinical trials, and more than 1843 gene therapy clinical trails have now been 
instigated worldwide (www.abedia.com/wiley/phases.php). 
1.6.2.2 : Adenoviral vectors. 
Adenovirus is double stranded DNA, non-enveloped icosohedral virus  first 
isolated in 1953 (Rowe et al., 1953). There are at least 52 serotypes that have 
been identified to cause humans infection. In general, most adenoviral 
infections cause respiratory illness with mild symptoms and require no 
treatment (CDC). In general, adenovirus infects host cells by binding to 
coxsackie adenovirus receptor (CAR) on the cell surface, and then the virus is 
internalized by interaction with α ν β integrins which act as co receptors 
(Russell, 2000). Following internalization, virus starts to express its genome 
through the host nucleus. Adenovirus genome can be divided into two regions 
according to the expression of gene: early region (E1A, E1B, E2A, E2B, E3, and 
E4) and late region (L1, L2, L3, L4, and L5). The E1A gene is the first 
transcriptional activator which activates the transcription of the other late 
genes. The E1A gene is important in virus replication and cellular 
transformation. The E1B gene inactivates the p53 protein to prevent apoptosis 
of host cell. The late gene protein products are essential for virus assembly and 
structural protein for the virus particles (W. C. Russell, Adenoviruses: update 
on structure and function, 2009). 
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1.6.2.3 : Replication deficient adenovirus vectors. 
In the first generation of replication-deficient adenoviral vectors E1 and often 
E3 were deleted and a transgene cassette being inserted into the E1 deleted 
region (Stratford-Perricaudet et al., 1990, Quantin et al., 1992). Removal of the 
E1 region from the adenoviral genome renders the virus replication-deficient 
and eliminates the potential for oncogenicity. Further deletion of the E3 locus 
increases the capacity for large insertion of transgene cassettes of up to 7.5 kb in 
size (Jolly, 1994). E1-deleted adenovirus can only propagate in supporting cell 
lines such as 911 or HEK293 cells due to the removal of removal of the E1A and 
E1B genes. Because 911 cells contain the nucleotide sequence 79-5789bp of the 
adenovirus type 5 genome and HEK 293 cells contain the left 11% of the 
adenovirus type 5 genome they can provide in trans the lost E1A and E1B 
functions (Graham et al., 1977, Fallaux et al., 1996). Regardless of the deletion of 
the E1 genes in this first generation of adenoviral vectors, a measurable amount 
of viral gene expression was still detected which was thought to be a result of 
either transactivation of viral genes by cellular factors similar to E1 gene, or a 
basal expression of the adenoviral promoters (Yang et al., 1995, Yang and 
Wilson, 1995). 
Next generation adenoviral vectors were rendered ‘gutless’ by removing all 
essential viral coding sequences. It has been reported that inserts totalling 35 kb 
can be inserted into a gutless adenoviral vector (Hardy et al., 1997). These kinds 
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of adenovirus vectors contain only the viral inverted terminal repeats and the 
packaging signal and therefore require the presence of a helper virus to enable 
their replication (Parks et al., 1996). The deletion of viral genes from the vector 
genome prevents the induction of a host immune response, allowing long term 
gene expression.  
 
1.6.2.4 : Replication competent adenovirus vectors. 
The promising development of conditionally replicating adenoviral vectors for 
cancer gene therapy creates the possibility of combining the effects of an 
inserted therapeutic transgene with the cytolytic effects of a replicating 
adenovirus. One approach to the issue of achieving tumour specific replication 
is controlling the expression of early region genes using tumour specific 
promoters. The prostate specific antigen (PSA) promoter is an example of 
driving expression of E1A specifically in prostate cancer, as the PSA is 
expressed at all stages of prostate cancers, but not in normal prostatic tissue 
(Rodriguez et al., 1997). Another example of a tumour-specific promoter is the 
α-fetoprotein (AFP) to drive E1A expression in hepatocellular carcinoma 
(Hallenbeck et al., 1999). In addition, using adenovirus with T cell factor (Tcf) 
binding sites in the early promoters has been found to specifically replicate in 
colon tumours where the Wingless integration site (Wnt) signalling pathway is 
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pathologically activated and leads to constitutive transcription from promoters 
containing (Tcf) binding sites (Fuerer and Iggo, 2002).  
Another strategy for the replication of tumour specific adenovirus is the exploitation 
of tumour specific defects in the control of cell replication such as the pRb and p53 
proteins. In normal cells, p53 is induced by activated oncogenes or by DNA 
damage. The p53 then activates the transcription of downstream effectors, 
resulting in cell cycle arrest or apoptosis of cells that may have acquired 
potentially tumourigenic lesions (Levine, 1997, Oren, 2003). However, in the vast 
majority of human tumours, the p53 tumour suppressor pathway is inactivated, 
either through direct mutation of p53 or as a result of the loss of upstream 
regulators such as p14ARF or downstream effectors such as Bax (Sherr and 
McCormick, 2002). In common with tumour cells, DNA viruses inactivate the 
p53 pathway, and many encode proteins that bind and degrade p53. Viral 
proteins that inactivate p53 are therefore believed to play a requisite role in 
viral replication by preventing p53-mediated cell cycle arrest or apoptosis. In 
the case of adenovirus, E1B-55K appears to fulfill this role, as together with E4-
ORF6 and cellular proteins involved in ubiquitination, it induces the 
degradation of p53 (Harada et al., 2002, Querido et al., 1997, Querido et al., 
2001). An example of this strategy was the development of the oncolytic 
adenovirus ONYX 015 by Onyx Pharmaceuticals from the adenovirus mutant, 
dl1520 that was originally described by Baker and Berk in 1987. The generation 
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of ONYX 015 was based on a mutant deletion of 827 bp from the E1 region, 
beside a point mutation that generates a stop codon preventing expression of 
the E1B 55 kDa protein and results in restricting viral replication to tumour cells 
that lack p53 (Barker and Berk, 1987, Bischoff et al., 1996). Despite the loss of 
E1B 55KDa expression it has been reported that ONYX 015 can replicate in 
some tumour cell lines with wild type p53 status (Goodrum and Ornelles, 1998, 
Hall et al., 1998). However, a recent study has indicated that the loss of E1B 55 
kDa mediates late viral RNA export which restricts ONYX 015 replication. RNA 
export of this type does not exist in normal cells and some tumours, indicating 
that E1B 55K-mediated late viral RNA export, rather than p53 degradation, 
restricts ONYX 015 replication in non-malignant cells (O'Shea et al., 2004). 
ONYX 015 has reached phase I/II clinical trials for head and neck  (Khuri et al., 
2000, Nemunaitis et al., 2000, Nemunaitis et al., 2001) ,pancreatic (Hecht et al., 
2003), ovarian (Vasey et al., 2002), liver (Makower et al., 2003), colorectal 
(Hamid et al., 2003), lung (Nemunaitis et al., 2001) and oral carcinoma (Ganly 
and Singh, 2003, Rudin et al., 2003). Moreover, a similar virus to ONYX 015 has 
now been developed in China named H101 or Oncorine, approved in 2005 by 
China’s State Food and Drug Administration for use in head and neck cancer 
(Guo and Xin, 2006).  
ONYX 411, similar to ONYX 015, was developed based on mutation within the 
conserved region 2 (CR2) domain of the viral E1A gene region. CR2 is required 
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for the E1A protein to bind to the retinoblastoma protein (pRb) and inactivate it. 
This blocks cell proliferation by sequestering and altering the function of E2F 
transcription factors that control the expression of many genes essential for 
progression from G1 into S phase (Hatakeyama and Weinberg, 1995). 
Disrupting the pRb pathway liberates E2Fs and allows cell proliferation, 
rendering cells insensitive to antigrowth factors. In many human cancers the 
pRb pathway is interrupted (Hanahan and Weinberg, 2011). Thus an 
adenovirus with a deletion mutation within the E1A CR2 region can normally 
replicate in tumour but not in normal cells. Adenovirus ONYX 411 was 
developed with further tumour specificity by controlling the E1A and E4 
expression by replacing their promoters with the E2F1 promoter, highly active 
in cells with an aberrant pRb pathway. ONYX 411replication was found to be 
dependent on pRb status of the cells (Johnson et al., 2002). 
 
1.6.3 : Clinical applications of adenoviral delivery of the TRAIL gene. 
The first report by Griffith (Griffith et al., 2000) of delivery of TRAIL by a 
nonreplicative adenoviral vector was in 2000 was followed by further reports 
that described the use of recombinant adenoviral vectors containing TRAIL 
cDNA (Armeanu et al., 2003, Zhang et al., 2008). A number of different studies 
have shown the potent effect of RAd TRAIL compared to the effect of the 
rshTRAIL on tumour cells. Administration of Ad5-TRAIL into tumour cells 
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show rapid transcription, translation and rapid expression of TRAIL protein. In 
addition RAd TRAIL was found to induce apoptosis in TRAIL receptor positive 
carcinomas and not normal cells. Sustained expression of TRAIL by Ad5-TRAIL  
in tumour model such as ovarian carcinoma (Seol et al., 2003) pancreatic 
carcinoma, hepatic carcinoma and lung carcinoma (Hait and Yang, 2006)  
 has resulted in potent induction of apoptosis compared to rshTRAIL with 
minimal cytotoxicity to normal cells.  
A Phase I clinical trial with RAd TRAIL in patient with prostate cancer have 
been completed. In this trial a direct injection of adenoviral expressing TRAIL 
into the prostate tumour has shown tumour regression and cell death without 
side effects. In addition, sustained TRAIL protein expression was observed after 
a single intratumoral injection of RAd TRAIL. Such expression of TRAIL would 
not be achievable with the administration of recombinant TRAIL protein 
(Griffith et al., 2000). Up to date several methods to enhance RAd TRAIL 
infection, distribution and expression of TRAIL gene are being investigated. 
 
1.6.4 : Systemic adminstration – based therapy. 
1.6.4.1 : Recombinant soluble TRAIL therapy. 
Since the first report of TRAIL in 1995, most of the studies have focused on its 
ability to induce apoptosis in tumour cell in vitro and in vivo, the target of those 
studies was to develop TRAIL as an antitumour therapeutic agent. Early studies 
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found that rsTRAIL induced apoptosis in a broad range of tumour cell lines, 
while having little to no activity against normal cells. Studies by Walczak et al in 
1999 to examine the antitumour effect of TRAIL in vivo by intravenous injection 
of soluble TRAIL demonstrated that there was no toxicity against normal 
tissues even with high concentrations and for long periods, whereas mice 
injected with low doses of FasL showed severe toxicity, necrosis and death after 
short time of treatment. Based on these results, TRAIL was suggested to be used 
as an anti-tumour therapy without the side effects or toxicity that seen with 
other TNF family members for example FasL and TNF. Up to date many clinical 
studies are evaluating the safety of Dulanermin the human recombinant TRAIL. 
Phase I and II clinical trial of Dulanermin in patients with sold or 
haematological tumours show the treatment to be well-tolerated.  Dulanermin 
alone or with different drugs such as Rituximab and Cetuximab as well as 
chemotherapeutic drugs such as Paclitaxel and Carboplatin has been evaluated 
for the safety and the efficacy on different tumour types. The results from these 
studies show that the half-life of Dulanermin is short (30-60 min) and may 
require multiple doses to achieve an effective antitumour response. Dulanermin 
bind receptor TRAIL-R1 and TRAIL-R2 and because of that it difficult to 
distinguish which is the specific receptor and whether the decoy receptors are 
influencing the drug activity. In addition, Dulanermin unlike agonist antibody, 
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dose not require exogenous Fcγ receptor interaction or cross-linking for its 
activity (Holland, 2011). 
 
 
1.6.4.2 : Anti-TRAIL antibodies therapy. 
The advantage of mAb over rsTRAIL is the long–life 14-21days (Plummer et al., 
2007). A number of mAb against TRAIL receptors have been used inclinical 
trails. The most investigated mAbs are Mapatumumab which is a fully human 
agonist IgG monoclonal antibody specific for human TRAIL-R1 and 
Lexatumamab agonist IgG monoclonal antibody specific for human TRAIL-R2. 
Mapatumumab is in phase II clinical trials. Studies found that mapatumumab 
can induce cytotoxic activity in vitro, and has the ability to inhibit growth of 
human tumour cells in xenograft models (Belyanskaya et al., 2007, Trarbach et 
al., 2010).  
 
1.6.4.3  : Combination of TRAIL and radiotherapy. 
Recombinant soluble TRAIL and TRAIL-receptor agonistic antibodies were 
shown to exhibit a high selectivity for tumour cells and act synergistically with 
conventional chemotherapy drugs and radiation. Up to date research has 
shown that radiotherapy strongly sensitises tumour cells to rsTRAIL and 
TRAIL-agonistic antibodies. Apoptosis induction in xenograft models was 
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observed with the combination of radiotherapy and sTRAIL and TRAIL-
agonistic antibodies, even in tumour cells with no or weak responses to either 
treatment alone. However, the efficiency of combined treatment is determined 
by different factors for example p53-status, the balance between pro- and anti-
apoptotic proteins and modulation of TRAIL-receptor signal transduction 
(Niemoeller and Belka, 2011). 
 
1.6.4.4 : Combination of TRAIL and chemotherapeutic drug strategies. 
Treatments of tumour cells with chemotherapy usually results in drug 
resistance which may be overcome by the combination with TRAIL (Mitsiades 
et al., 2001). Therefore combination of cytotoxic drugs with rsTRAIL has been 
tested in preclinical models for synergy and the ability to reduce cancer drug 
resistance. Results of phase I/II clinical trails of rsTRAIL in combination with 
chemotherapy drugs are encouraging (Soria et al., 2011). 
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1.7 : Thesis objectives. 
Previous results from our lab and others have demonstrated the efficacy of 
membrane-bound CD40L and FasL in cell death induction and apoptosis 
compared to soluble or wild-type counterparts. Given that both CD40L and 
TRAIL belong to the same family and they share a significant homology (25-
30%)(Pitti et al., 1996). In view of the potential therapeutic role of rsTRAIL in 
carcinoma, the objective of this thesis was to generate a RAd virus expressing 
wild-type TRAIL and to examine the direct effect of this virus alone or in 
combination with cytotoxic and novel drugs on TRAIL receptors-positive 
carcinomas. Furthermore, to examine the direct effect of blocking of the TRAIL 
cleavage from membrane in RAdwtTRAIL-infected cells on cell viability 
reduction and apoptosis induction. Moreover, to generate a RAd virus 
expressing a membrane-bound TRAIL mutant resistant to cleavage from 
membrane by hybrid fusion between the CD40L N-terminal domain  (1-324bp) 
upstream of the CD40L cleavage site (324-348bp) and the C-terminal domain of 
TRAIL ligand (340-846bp, containing the TRAIL active site) and we examine the 
direct effect of this virus alone or in combination with cytotoxic and novel 
drugs on TRAIL receptors-positive carcinomas. Also, to investigate the possible 
mechanism responsible for TRAIL-induced cell death caused by the membrane 
bound-non cleavable TRAIL. 
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Unless otherwise stated, all reagents and materials were obtained from Sigma- 
Aldrich, Poole, UK 
2.1 : Molecular Biology techniques. 
2.1.1 : PCR amplification for molecular cloning. 
The primers and annealing temperatures were optimized according to each 
primer and product size of each Polymerase Chain Reaction (PCR) reaction. The 
PCR reaction briefly   contains 1µl of forward and reverse primer (50pmol/µl) 
(synthesised by Alta Biosciences, University of Birmingham, UK), 50ng of DNA 
template, 5µl of 10x expand high fidelity buffer (Roche), and ddH2O to 
complete the total volume up to 49µl, the PCR reaction was then heated to 93°C, 
Followed by addition of, 1µl of high fidelity proof reading Taq enzyme 
(3.5U/µl) (Roche) as a hot start reaction.  PCR reactions were allowed to cycle in 
a Gene Amp PCR 2400 system (Perkim-Elmer) according to the conditions 
described in Table 2.1. 
Table 2. 1: Primers and PCR conditions used in molecular cloning. 
Name Oligonucleotide Tm PCR Cycle 
TRAIL 
Sal1 F 
5’-A GTCGAC ATG-GCT-
ATG-ATGG-AGG-TC-3’, 
58.1 
(93°C5mins (93°C 30 Sec, 
58.1°C, 45 Sec, 72°C 2 mins) x 
25, 72°C, 5 mins) 
TRAIL 
Xba1 R 
5’ C- TCTAGA –TTA-GCC-
AAC-TAA-AAA-GGC-CC-3’ 
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2.1.2 : Agarose gel electrophoresis. 
 Agarose (Gibco, Paisley UK) gel was prepared by melting the required 
quantity in TBE buffer (89mM Tris base, 89mM boric acid, 2.5mM EDTA, pH 
8.3) ethidium bromide was then added at a concentration of 0.2µg/ml before gel 
solidification. The solution was subsequently poured into the preassembled 
tray and all bubbles were removed. The gel solution was then left until 
solidified and covered with TBE buffer. The DNA samples were mixed with the 
corresponding volume of 6x loading buffer (100mM Tris HCl, pH 7.5, 20% (v/v) 
Glycerol, 1mM EDTA, few drops of Bromophenol blue) and loaded into the gel. 
The gel was run at 100V until the separation was optimal. Gel was visualized 
under UV light. 
 
2.1.3 : Purification of DNA from agarose. 
The desired DNA fragment was visualized by using minimum UV exposure to 
avoid DNA degradation. The DNA fragment was excised from the gel and 
DNA was extracted from the agarose gel by Qiagen gel extraction kit (West 
Sussex, UK) according to the manufacturer’s instructions. Following the 
extraction the DNA was eluted by adding 30µl of pre-warmed sterile water and 
stored at -20°C. 
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2.1.4 : Addition of A-overhangs to the PCR products for sub-cloning into 
TOPO vectors. 
The reaction mixture was prepared by mixing 5µl of 10x PCR Buffer, 1µl of 
dNTPs (2.5mM of each nucleotide) and 0.5µl of Taq polymerase (New England 
BioLabs), 18.5µl ddH2O was then added to bring  the final volume up to 25µl. 
The reaction mixture was incubated in the Gene Amp PCR 2400 system 
(Perkim-Elmer) for 20 minutes at 72°C. 
 
2.1.5 : Purification of A-overhanged PCR product. 
PCR reaction was mixed with PB buffer supplied within the Gel extraction 
Qiagen kit (West Sussex, UK) at 1:5 volume. The samples mixture was 
processed according to the manufacturer’s instructions. DNA was then eluted 
in 30µl of pre-warmed sterile water and stored at -20°C or used immediately in 
TOPO cloning reactions. 
 
2.1.6 : TOPO-cloning reaction. 
Linearized pCR®TOPO2.1 plasmid vectors from (Invitrogen) was ligated with 
the A-overhanged PCR product. The ligation reaction was prepared according 
to the manufacturer’s instructions. The ligation reaction was incubated 
overnight at 16°C and was used for transformation or stored at -20°C. 
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2.1.7 : Vector-insert ligation. 
The concentration of the insert and the pre-digested and gel purified plasmid 
was estimated on an agarose gel. Approximately 1:1 or 1:2 vector : insert DNA 
were added to a ligation reaction containing 2μl of 10x T4 ligase buffer, 1μl of 
T4 ligase and sterile water to make up the final volume of 20μl. The reaction 
mixture was incubated overnight at 16°C. 2μl of the reaction was used to 
transform 50µl of Top10 F competent cells. 
 
2.1.8 : Preparation of chemically competent cells. 
One millilitre of overnight-cultured bacteria in LB medium was used to 
inoculate 500ml of prewarmed LB broth, bacteria was allowed to grow to 0.2 
OD600 (2-3 hours), then chilled on ice for 10 min followed by  centrifugation  at 
5000-6000 rpm at 4ºC for 10 min. Bacterial pellet was resuspended in 250ml of 
Transformation Buffer-X (50mM CaCl, 15%(v/v) Glycerol, 10mM MOPS pH 6.6 
(with NaOH only), filtered and sterilized). The resuspended cells were 
incubated on ice in sterile falcon tube for 20 min and centrifuged again for 10 
mins (5000-6000 rpm, 4°C). The pellet was resuspended in 2.5ml of 
transformation buffer-X. Aliquots of 100μl of the cells were prepared into 1.5ml 
microfuge tubes with fast frozen in liquid nitrogen and stored at -80C. 
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2.1.9 : Preparation of electro competent cells. 
1ml of the overnight bacterial culture grown in LB medium was inoculated into 
500ml of pre-warmed LB broth and grown to 0.3-0.6 OD600 (30-60 minutes).  
Cells were transferred into 50ml falcon tube and incubated on ice for 30 minutes 
then pelleted at 5000-6000 rpm at 4°C for 10 minutes. Cells were washed in 
250ml ice cold sterile ddH2O and spun  again for 10 minutes at 5000-6000 rpm at 
4°C. The washing step was then repeated 3 times using 50ml ice cold sterile 
ddH2O.  Cells were then washed in 50 ml sterile ice cold 10% glycerol, followed 
by resuspension in 2.5ml sterile ice cold 10%. 100μl aliquots of the cells were 
prepared into 1.5ml microfuge tubes, fast frozen in liquid nitrogen and directly 
stored at -80C.  
 
2.1.10 : Bacterial transformation.  
2.1.10.1 : Heat-shock bacterial transformation of home-made competent cells. 
100μl of aliquot competent cells was chilled on ice for 10min to thaw then 2-5µl 
of DNA was added and the cells were incubated on ice for 30 minutes followed 
by heat shocked for 5 minutes at 37C and cooled on ice for 2 minutes. 400μl of 
recovery SOC medium (L-broth supplemented with 20mM glucose, 2.5mM KCl 
(pH 7) and 10mM MgCl2) was added to the transformed cells and allowed to 
recover for 1hr at 37C in an orbital incubator. After recovery cells were plated 
on selective LB-agar plates (500ml solutions require 10g LB broth base (Gibco) 
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and 7.5g selected agar (Gibco), autoclaved and supplemented with an 
appropriate concentration of the selection antibiotic). Plates were incubated 
overnight at 37C. 
 
2.1.10.2 : Bacterial transformation by electroporation. 
About 20μl of electrocompetent E.coli BJ5183 cells were placed in a 2.0mm pre-
cooled cuvette and placed on ice for 5 minutes. DNA was added to cells and 
incubated for 5 minutes on ice. The mixture was electroporated at 2,500 V, 200 
ohms, and 25µF in a Bio-Rad Gene pulser electroporator. Immediately after the 
pulse, cell mixture was transferred to 500µl of SOC medium and incubated at 
37C with vigorous shaking for 1 hour. Then cells were plated on selective LB-
agar plates supplemented with an appropriate concentration of the selection 
antibiotic and incubated overnight at 37C. 
 
2.1.11 : Isolation of DNA from mini-prep and maxi-prep cultures.  
To extract plasmid DNA, 1.5ml of an overnight bacterial culture was processed 
with the Qiagen mini-prep kit according to the manufacturer’s protocol 
(Qiagen, West Sussex, UK). To maxi-prep plasmid DNA, 100µl of the mini-prep 
culture was incubated at 37C for 16 hours with 100ml of antibiotic-containing 
LB medium. After the bacteria had propagated, glycerol stocks of the plasmid 
were made by thoroughly mixing 500µl of crude culture with 500µl of sterile 
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glycerol and stored at -70C. Plasmid DNA was extracted using the Qiagen 
maxi-prep kit according to the manufacturer’s instructions. Isolated DNA was 
re-dissolved with TE buffer (10mM Tris HCl pH 8, 1mM EDTA) and diluted to 
1µg/µl stock solution.  All plasmids were stored at -20C. 
 
2.1.12 : Restriction digests. 
To digest purified plasmid DNA, 5µl of DNA was mixed with 10U restriction 
enzyme in total volume of 20µl, or 0.5-1µg of maxi-prep DNA was digested in a 
total volume of 20µl with 10U restriction enzyme (Roche, Lowes, UK) and the 
appropriate 10x concentrated buffer (Roche, Lowes, UK). Mixture was 
incubated at the optimal temperature then analysed by gel electrophoresis.  
 
2.1.13 : Phenol/chloroform extraction of digested DNA.  
Phenol/Chloroform mixture was mixed with an equal volume of digested DNA 
(1:1). The reaction mixture was centrifuged for 10 minutes (13000 rpm, 4C). 
Then upper phase was transferred to a new 1.5ml eppendorff tube and 
thoroughly mixed with an equal volume of chloroform then centrifuged for a 
further 10 minutes. Again the upper phase was transferred to a new eppendorff 
tube and 0.1 volume of either 2M NaCl or 3M sodium acetate was added. 
Isopropanol was added to mixture at an equal volume for DNA precipitation, 
the mixture was then incubated at -20C for 2 hours followed by centrifugation 
Chapter 2                                                                                        Materials and Methods 
61 
for 10 minutes (12000 rpm, 4C). The DNA pellet was washed twice with 70% 
ice cold ethanol and air-dried before dissolving in an appropriate volume of TE 
buffer.   
 
2.1.14 : Isolation of RNA. 
All procedures were performed on ice with ice-cold solutions and RNase free 
plugged tips. 1x106 cells were trypsinised, washed once with PBS, resuspended 
with 200l RNAzol (Biogenesis Ltd, Poole, UK) and 0.1 volume of chloroform. 
Samples were mixed vigorously by vortex for 15 seconds, incubated on ice for 5 
minutes and centrifuged at 13,000rpm for 15 minutes at 4oC. The top aqueous 
phase was transferred to a pre-chilled eppendorf and an equal volume of 
iosopropanol (Fisher Scientific, Loughborough, UK) added and vortexed 
thoroughly. Samples were incubated at –20C for 1 hour and centrifuged at 
13,000rpm for 15 minutes at 4C. The resultant supernatant was decanted, the 
RNA pellet washed with 500l 70% ethanol and re-centrifuged at 13,000rpm for 
15 minutes at 4C. The ethanol was aspirated and the air-dried pellet was re-
dissolved in 10-20l DEPC-treated water and stored at -70C 
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2.1.15 : cDNA synthesis. 
The cDNA was synthesised by using the RETROscript® RNase reverse 
transcriptase kit (Ambion Europe) according to the manufacturer’s instructions. 
Briefly, 2µg of RNA was mixed with 2µl of 50µM Oligo (dT) in a total volume 
of 12µl SDW, and heated to 85oC for 3 minutes. The mixture was quickly chilled 
on ice and briefly centrifuged then 4µl of dNTP mix (2.5mM each dNTP), 2µl of 
10X RT buffer, 1µl of RNase inhibitor (10 units/µl) and 1µl of MMLV-RT (100 
units/ml) were added. The reaction was then incubated at 42C for 1 hour 
followed by inactivating the reverse transcriptase at 92C for 10 minutes. cDNA 
products were stored at -20C and not repeatedly freeze-thawed. 
 
2.1.16 : PCR amplification of cDNA. 
1µl of Real-Time polymerase chain reaction (RT-PCR) cDNA product was 
incubated in a PCR rea ction tube containing 50pmol of forward and reverse 
primer (Table 2.2), 5µl x10 buffer (Bioline, London, UK), 200mM dNTP (Roche), 
1.5mM MgCl2 and 0.5µl Taq polymerase (Bioline) in a total volume of 50µl. The 
reaction mixture was done in Perkin Elmer DNA Thermal Cycler as described 
in Table 2.2. 
 
 
 
Chapter 2                                                                                        Materials and Methods 
63 
 
Table 2. 2: Primers and PCR conditions used for RT-PCR reactions 
Name Oligonucleotide Tm PCR Cycle 
GAPDHF244 5’CCT CCA AAA TCA AGT GGG GCG 3’ 
61.8 
93C 4 mins 
(93C 30 Sec, 
61.5C, 45 Sec, 
72C 2 min) x 26, 
72C, 5 mins 
GAPDHR845 5’ACC ACC AGG TGC TCA GTG TAG 3’ 
TR1F  5'-GGAGAGTTGTGTCCACCAG-3'  
TR1R 5'-CGAGTCTGCGTTGCTCAGA-3'  
TR2F 5'-ACGGTAGAGATTGCATCTCC-3'  
TR2R 5'-TGAGCTTCTGTCCACACGC-3'  
TR3F 5'-CCTGTAACCCGTGCACAGA-3'  
TR3R 5'-GGGCTGGTGGTCATTGTC-3' 
TR4F 5'-GCACAGAGGGTGTGGATTAC-3' 
TR4R 5'-GGTGGGCTGCAAGTATCTG-3' 
TR5F 5'-ATGCAAGGAAGGGCGCTAC-3' 
TR5R 5'-CCAATGTGCCGCTGCAC-3' 
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2.1.17 : Generation of TRAIL mutants using site-directed mutagenesis. 
Deletion mutations within the human TRAIL were generated from 
pShuttlewtTRAIL vector using the Quick Change site-directed mutagenesis kit 
(Strategene Europe, Amsterdam, The Netherlands). The forward primers 
TRAILde105-108F and TRAILde105-115F and the reverse primers TRAILde105-
108R and TRAILde109-115R (Table 2.2) were utilised for generating the TRAIL 
mutants with deletion mutation 105EKQQ108 or the 105 EKQQHISPLV115   
respectively. Primers were designed such that the Tm was greater than 72C.  
Briefly, PCR reactions contained 125ng of each forward and reverse primers, 
50ng of pShuttlewtTRAIL template DNA, 200M dNTP and 2.5U Pfu 
polymerase in a total volume of 50l were heated to 95C for 30 sec, followed 
by 16 cycles of 95C for 30 seconds, 55C for 1 min and 68C for 2 min per kb of 
plasmid length.  Finally, the reaction was cooled to 4C.  To get red of the non-
mutated parental DNA strand, PCR reactions were treated for 1 hour at 37C 
with 10U Dpn I enzyme. 1l of the reaction was used to transform 50l of XL-1 
Blue supercompetent E. coli (Strategene Europe, Amsterdam, The Netherlands) 
and the resultant colonies formed on L-agar plates were further grown for mini-
prep analysis. 
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Table 2.3: Primers and PCR reaction conditions for generating TRAIL mutants. 
 
Name Oligonucleotide Tm PCR Cycle 
TRAILde105-108F 5’ GGA AAC CAT TTC TAC AGT TCA 
AAA TAT TTC TCC CCT AGT G 3’  
72C 
93C 4 mins 
(93C 30 
Sec, 59.1C, 
45Sec, 72C 
2 min) x 26, 
72C, 5 
mins 
TRAILde105-108R 5’ CAC TAG GGG AGA AAT ATT TTG 
AAC TGT AGA AAT GGT TTC C 3’ 
TRAILde105-115F 5’ GAG GAA ACC ATT TCT ACA GTT 
CAA GAA AGA GGT CCT CAG AGA-
GTA-GCA-GC-3’ 
TRAILde109-115R 5’-CTC-CTT-TGG-TAA-AGA-TGT-
CAA-GTT-CTT-TCT-CCA-AGA-GTC-
TCT-CAT-CGT-CG 3’ 
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2.2 : Tissue culture techniques. 
2.2.1 : Maintenance of cells lines. 
Different carcinoma cell line as shown in (Table 2.3) were maintained  in D-
MEM supplemented with 10% foetal calf serum (Gibco, Paisley, UK) and 1% 
penicillin/streptomycin (final concentrations: 100U/ml penicillin, 0.1mg/ml 
streptomycin). Cells were grown in vented 75cm2 or 150cm2 flasks (Iwaki, 
Japan) at 37C in 5% CO2, and routinely passaged when 90% confluent or every 
2-3 days. The media was removed, cells washed once with PBS, and diluted 
trypsin (0.5% w/v trypsin, 0.02% w/v EDTA in a total volume of 20ml PBS) 
added to cover the cells. Cells were transferred to complete media and pelleted 
by centrifugation at 1000rpm for 5 minutes. The cell pellet was resuspended in 
fresh complete media and plated into a 75cm2 or 150cm2 flasks. 
Table 2.4: Carcinomas cell lines used in this thesis. 
Name of cells line Origin 
HepG2 Human hepatic cell carcinoma  
Hela Human cervical carcinoma 
OVCAR-3 Human ovarian cell carcinoma 
SKOV-3 Human ovarian cell carcinoma 
A2780 Human ovarian carcinoma 
EJ Bladder carcinoma 
HEK 293 Embryonic kidney 
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2.2.2 : Freezing and thawing cell stocks. 
About 2x106 pelleted cells were resuspended in 1ml of freezing media (complete 
media supplemented with 10% DMSO (Fisher Scientific, Loughborough, UK)) 
and transferred to a 1ml vial (Nunc, Nalge Europe Ltd, Hereford, UK). The 
vials were placed at -80C in a cooling box for at least 24 hours and then 
transferred to liquid nitrogen storage. Cells were recovered by thawing vials 
quickly at 37C and transferring into 10ml pre-warmed complete media for 1 
minute before centrifugation. Cells were resuspended in complete media and 
transferred to a 75cm2 flask and incubated at 37C in 5% CO2.  
 
2.2.3 : Transfection of cells with plasmid DNA. 
For  cell transfection, cells were seeded at 3x105 cells/30mm dish in complete 
media and the next day transfected overnight using the jetPRIME® Plus kit 
according to the manufacture’s instructions. Briefly, 3-5µg DNA was 
resuspended into 200μl jetPRIME® buffer, 4μl jetPRIME was then added to the 
DNA mix and incubated for 10 minutes. The mixture was then added to the cell 
culture drop by drop and distributed evenly. After 24 hours transfection 
medium was replaced by complete media and incubated at 37C/5%CO2. 
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2.2.4 : Production of recombinant adenovirus. 
2.2.4.1 :Generation of recombinant adenoviral plasmids by homologous 
recombination in E. coli.  
Typically, 1.0µg of pAdShuttle-CMVTRAIL-CD40L or pAdShuttle-CMV empty 
vector plasmid were linearized with PmeI, purified by phenol/chloroform 
extraction, and mixed with 0.1µg of pAdEasy-1 in a total volume of 6µl. The 
DNA mixture was used to transform 20µl of electrocompetent E. coli BJ5183 
cells by electroporation method. The cell suspension was then plated onto LB-
agar medium containing 50µg/ml kanamycin and incubated at 37°C until 
colonies showed up. The smaller colonies (which usually represented the 
recombinants) were picked up and grown in 2ml of L-Broth containing 50µg/ml 
of kanamycin. Clones were first screened by analyzing their supercoiled sizes 
on agarose gels, comparing them to pAdEasy-1 control. Those clones that had 
inserts were further examined by Pac1 restriction endonuclease digestion. Once 
confirmed, supercoiled plasmid DNA was transformed into Topo 10F 
chemically competent cells for large-scale DNA amplification. 
 
2.2.4.2 : Production of adenoviruses in mammalian cells.  
Approximately 1.5 x106 of 911 or HEK 293 cells were plated in 25cm2 flasks 24 
hours before transfection, by which time they reached 50–70% confluency. Cells 
were washed BPS and incubated for 4 hour with jetPRIME as described in 
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section 2.2.3. 4µg of recombinant adenoviral vector DNA, digested with PacI 
and phenol/chloroform purified was used for transfection of each 25cm2 flask. A 
transfection mix was prepared by adding 4µg of linearized plasmid DNA 
according to the manufacturer’s instructions. Transfected cells were monitored 
for cytopathic effect and collected 7-10 days after transfection by scraping cells 
off flasks and pelleting them along with any floating cells in the culture. The 
supernatant was discarded and the cell pellets were re-suspended in 2ml sterile 
PBS and viral particles were extracted by vigorous mixing with an equal 
volume of Arklone P and spinning for 10 minutes at 2000rpm. The viral 
containing solution was collected and stored at -80°C or used to infect 3–5 x 106 
293 cells in a 25cm2 flask. Four days later, viruses were harvested.  
 
2.2.4.3 : Large scale production of the recombinant adenovirus. 
For large-scale recombinant adenoviral production, HEK 293 cells were plated 
out into twelve 150cm2 flasks (IWAKI). When the cells 80% confluent the 
complete growth medium was replaced with 5ml 2% FCS D-MEM with 1:100 
dilution of the adenoviral extract obtained from 2.2.4.2. After 6 hours cells were 
supplemented with an additional 12ml of 2% FCS D-MEM medium, zVAD with 
final concentration 15µM to prevent cell death and incubate at 37C. 5-6 days 
post-infection, cells and medium were transferred to a 50ml tube and 
centrifuged at 2000rpm for 5 minutes at room temperature. The supernatant 
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was discarded and the cell pellets were re-suspended in 10ml sterile PBS and 
viral particles were extracted by Arklone P as described in section 2.2.4.2.  
 
2.2.4.4 : Density gradient purification of adenovirus. 
In Beckman polycarbonate tube a 2ml of р=1.32 CsCl (32.0g CsCl, 6.8 ml 0.5M 
Tris pH 7.9 and 61.2ml SDW) was added, followed by 3ml of р =1.45 CsCl 
(20.5g CsCl, 2.9ml 0.5M Tris pH 7.9 and 25.8ml SDW) drop by drop. Then on 
top of this, 2ml of 40% glycerol (40g glycerol, 2ml  0.5M Tris pH 7.9 and 0.5ml 
0.2M EDTA, 57.5ml SDW) was added, followed by the addition of the crude 
adenoviral extract slowly so as not to disturb the CsCl gradient. The tubes were 
topped up with PBS buffer to just below the brim. Tubes were placed in an 
SW40 rotor in a Beckman Coulter OptimaTMLE-80K ultracentrifuge and spun at 
25000rpm for 2 hours. After the ultra centrifugation two bands could be clearly 
seen in the tube. The lower band containing the wanted virus was extracted by 
piercing the tube with a 21-gauge needle allowing the virus to be withdrawn. 
Viruses were collected and injected into a Slidealyser (3M) 10,000MW dialysis 
cassettes. Dialysis cassettes were incubated for 4 hours in dialysis buffer (10mM 
Tris-HCl, pH 8.0, 2mM MgCl, and 5% sucrose) at 4C with gentle agitation then 
buffer change and left overnight. Buffer was changed at least four times to 
ensure all CsCl was removed. The viruses were removed from the Slidealyser 
and aliquoted into 100μl and stored at -80C.    
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2.2.4.5 : Measurement of virus concentration. 
Using Adeno-X™ Rapid Titer Kit for viral concentration. HEK 293 cells were 
cultured in 2% FCS D-MEM at 2.5 X 105 cells/ml and plated in 24-well plate. 
Virus stock was serially diluted with 2% FCS D-MEM as from 10-2 to 10-7 and 50 
µl of viral dilution were add to each well. Cells were incubated at 37°C in 5% 
CO2 for 48 hours then assessed according to the manufacture’s instructions. The 
virus concentration was calculated in ifu/ml (Infection Forming Unit).  
 
2.2.4.6 : Infection of cells with replication deficient adenoviruses. 
Cells were seeded in complete media at 5000-7000 cells per well in a 96-well 
plate for apoptosis or caspase activation assays, or 3x105 cells/30mm dish for 
western blotting analysis. Cells were infected in 10% FCS D-MEM for 2 or 
infected for 24 hours at 37C with the appropriate MOI of the adenovirus. 
Culture medium was then replaced by fresh medium and incubated at 37C.   
 
2.2.4.7 : Chemotherapeutic treatment of cells. 
Cells infected with virus or left without infection were cultured in 96 well plate 
at a density of 5-7 x 103 cells/ well for 24 hours .Cells were then treated with 
different cytotoxic drugs at different concentration [Sorafunib (Sor), 
Doxorubicin (DOX), 5 Fluorouracil (5FU), Cisplatine (Cis), Pacletoxel (Pac)]. 
After 48 hours, cell viability was evaluated by WST1 assay. 
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2.2.5 : Analysis of cell viability by WST-1 assay. 
Cells  were infected  with the adenoviruses (RAd) at an appropriate MOI dose 
for 2 hours and then plated out in 96-well plate in 10% FCS D-MEM medium f 
at 5000-7000 cell/100µl/well and incubated at 37C for either 24, 36 or 48 hours.  
Cell viability was then assessed by the WST-1 assay reagent (Roche), briefly, the 
WST-1 reagent was added at 1:10 dilution of the total volume of culture 
medium. Plates were incubated at 37C and the OD was then measured by 
microplate ELISA reader at λ450 every 30min up to 3 hours from the time of 
adding the WST-1 reagent. The number of metabolically active cells is directly 
correlates to the amount of formazan formed. 
 
2.2.6 : Caspase 3/7 activation measurement assay. 
 Carcinomas cell lines were grown in complete 10% FCS D-MEM and infected 
with either RAdMock or RAdwtTRAIL or RAdncCD40LTRAIL or treated with 
rshTRAIL (100-200ng/ul) described in section 2.2.4.6 or left un-infected as a 
control.  Cells were either treated with the general caspase inhibitor ZVAD at a 
concentration of 30µM. Cells were cultured in a white-walled tissue culture 96 
well plate at density of 5000 cell/100µl/well in triplicate and incubated in a 37C 
incubator for 36 hours. The activity of caspases 3/7 was measured using the 
Caspase-Glo® 3/7 (Promega, UK) assay kit according to the manufacturer’s 
instructions. The caspase reagents were prepared and 100µl/well was added to 
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cells, mixed for 30 sec in a 96 well plate shaker at room temperature followed by 
1 hour incubation at room temperature. Luminescence was then measured 
using a 96-well plate luminometer. The result of luminescent signal is directly 
proportional to the amount of caspase activity present in each sample. 
 
2.3 : Protein biochemistry techniques. 
2.3.1 : Preparation of protein extracts.  
2.3.1.1 : Preparation of protein extracts from mammalian cells. 
For protein extraction, cultured cells were washed three times with ice cold 
PBS. Cells were then lysed in situ with a suitable volume of an appropriate 
concentration of NP-40 lysis buffer. Total cell lysates were collected and 
incubated on ice for 30 minutes for complete lysis. Lysates were then clarified 
by centrifugation at 13,000rpm for 15 minutes at 4C and stored at -80C. 
2.3.1.2 : Determination of protein concentration. 
Protein concentration was determined using the Protein Determination assay 
kit (BioRad Lab Ltd., Hemel Hempstead, UK ) by mixing 2.5µl of clarified 
lysates with 1.2ml SDW and 300µl BioRad reagent (Biorad Lab. Ltd., Hemel 
Hempstead, UK). Then Absorbance at λ450 was measured by 
spectrophotometer and protein concentration calculated in reference to the BSA 
standard curve. 
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2.3.2 : Immunoblotting techniques. 
2.3.2.1 : SDS-PAGE electrophoresis. 
Western blotting was performed using a Mini-Protean III tank (BioRad) by the 
method of Laemnli. Glass plates were cleaned with ethanol and the apparatus 
assembled according to the manufacturer’s instructions. 10ml resolving gel 
(375mM Tris-HCl (pH 8.8), 0.1% SDS, 0.1% ammonium persulfate, 30% (w/v) 
acrylamide/0.8% (w/v) bis mix (National Diagnostics, Geneflow Ltd, Fradley, 
UK) and TEMED depending on the desired percentage of gel) was poured. 
Water saturated butanol was layered on top of the resolving gel to remove air 
bubbles. Gels were allowed to set at room temperature until solidified. 
Saturated butanol was thoroughly washed out with distilled H2O. A 4ml 
stacking gel was prepared (125mM Tris-HCl (pH 6.8), 0.1% SDS, 0.1% 
ammonium persulfate, 0.01% TEMED and 0.67ml 30% (w/v) acrylamide/0.8% 
(w/v) bis mix) and poured on top of the set resolving gel, a comb inserted and 
allowed to set at room temperature. Prior to gel loading, the comb was removed 
and the wells washed extensively with x1 SDS-PAGE running buffer (x10 stock 
solution; 0.25M Tris-HCl pH 8.3, 1.92M glycine and 1% (w/v) SDS). Samples 
containing 15-100µg of total protein were denatured by boiling with 3x 
concentrated gel sample buffer (GSB; 187.5mM Tris-HCl pH 6.8, 6% w/v SDS, 
30% glycerol, 0.03% w/v bromophenol blue, 150mM DTT) for 5 minutes.  
Denatured samples were cooled on ice, pulse centrifuged to remove 
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condensation and loaded onto the assembled gel.  Gels were electrophoresed at 
120-150V (constant voltage) for 90-120 minutes.  
 
2.3.2.2 : Western blotting. 
Following SDS electrophoresis, transfer of proteins was performed using the 
BioRad Mini Trans-Blot tank onto nitrocellulose transfer membranes (Pall 
Gelman laboratory, Portsmouth UK) or methanol soaked 0.45µM PVDF 
membranes (Millipore, Watford, UK). Tanks containing transfer buffer (50mM 
Tris-HCl, 190mM glycine, 20% (v/v) methanol) and assembled mini gel holder 
cassettes were placed on a magnetic stirrer to prevent the build up of heat and 
electrophoresed for 1 hour at 100V. Membranes were washed in TBS-T (1x TBS; 
20mM Tris-HCl pH 7.6, 136mM NaCl, supplemented with 0.1% Tween-20) for 5 
minutes and blocked in TBS-T containing 5% low-fat milk or 5% of BSA 
(phosphrylated proteins) for 1 hour at RT. Blocked membranes were then 
washed three times for 5 min in TBS-T and incubated overnight at 4C in the 
relevant primary antibody (Table 2.4).  Membranes were washed three times for 
5 minutes each in TBS-T, incubated for 1 hour at RT in the relevant peroxidase 
conjugated secondary antibody (Table 2.6) diluted in TBS-T, and then washed a 
further 3 times for 5 minutes each in TBS-T. Proteins were visualised by 
enhanced chemiluminescence (Amersham).  
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Table 2.5: Primary antibodies. 
 
 
 
 
 
 
 
Table 2.6: Secondary antibodies. 
Antigen Dilution Supplier 
α-Goat HRP 1:4000 Santa Cruz 
α-mouse HRP 1:5000 Sigma 
 
 
 
 
  
Antigen Dilution Secondary Supplier 
TRAIL (C-19) 1:500 α- goat Santa Cruz 
β-Actin 1:10000 α-rabbit Cell Signaling 
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2.3.3 : Enzyme-linked immunosorbent assay (ELISA). 
Cultured cells in 10 % FCS D-MEM medium were infected with at different 
MOI of either RAdwtTRAIL, RAdncCD40LTRAIL or RAdMock or left without 
infection. Then cells plated at 5000-7000 cell/well in 96-well microplates. Twenty 
four hours later cells were treated with 15µM of MMPI I and II (MPI) or left 
without treatment for 24 hours. Samples from culture media were collected 
after 48 hours for assessing the sTRAIL concentration by ELISA assay kit 
according to manufactures instruction. Briefly, the sTRAIL standard 
concentrations, in addition to the collected samples, were applied in a total 
volume of 100µl of the diluent provided within the kit in duplicate to a 
microwell plate coated with anti-human sTRAIL monoclonal antibody. A 100µl 
of diluted HRP-conjugate anti-sTRAIL (1:200) monoclonal antibody was added 
to each well. The plate was covered with a plate cover and incubated for 2 
hours at room temperature then carefully washed three times with 300µl wash 
buffer. 100µl of substrate solution was added to each well and incubated for 10 
min at RT on a rotator set at 100rpm. The reaction was stopped by adding 100µl 
of stop solution into each well. The absorbance of the colour product was 
measured within 30 minutes at λ450 using an ELISA plate reader. 
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CHAPTER 3 
GENERATION OF REPLICATION-DEFICIENT ADENOVIRUS 
(RAd) EXPRESSING WILD TYPE-TRAIL 
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3.1 : Introduction. 
The utility of TNF ligands in cancer treatment is promising due to their ability 
to induce cell death and apoptosis.  Since the discovery of TNF in 1975 
(Carswell et al., 1975), administration of TNF has been found to induce cell 
death or growth regression of solid human tumours xenotransplanted into 
SCID mice (Haranaka et al., 1984), the induction of TNF-family ligands for 
cancer treatment has promised to be an attractive in addition to the classical 
strategy of treatment cancer with chemotherapy and radiotherapy. Induction of 
apoptosis in tumour cells through death-domain containing TNF receptor 
family member is rapid and involves the extrinsic pathway with the cleavage of 
caspase 8 and activation rather than mitochondrial–mediated pathway. Recent 
studies have revealed the ability of death receptor ligands of the TNF family to 
sensitize drug-resistant carcinomas such as ovarian carcinoma (Vignati et al., 
2002). 
The findings that TRAIL induces apoptosis in tumour but not normal cells, and 
that combination of TRAIL with other chemotherapeutic drugs or radiation can 
induces a higher degree of cell death and apoptosis in carcinomas than either 
agent alone (Chinnaiyan et al., 2000), have highlighted the potential therapeutic 
role of TRAIL in cancer treatment. To date, several methods have been used to 
deliver TRAIL into the tumour mass, including direct delivery of TRAIL via 
systemic administration of recombinant soluble TRAIL (rshTRAIL) or agonistic 
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monoclonal antibodies (mAbs) (reviewed in Mellier et al., 2010)  and these have 
been tested in clinical trials. Results show that  both rshTRAIL and mAbs are  
promising but required repeated administration and large doses of TRAIL 
(reviewed in Holoch and Griffith, 2009).  
An alternative route of administration involves a gene therapy approach to 
deliver TRAIL cDNA into the tumour cells. Recent studies of TRAIL gene 
therapy have demonstrated that ex vivo infection of cancer cells with a 
recombinant adenovirus expressing TRAIL (RAdTRAIL) enhances apoptosis 
and promotes tumour regression (Zhang et al., 2008). Direct administration of 
TRAIL gene by RAdTRAIL into human prostate cancer leads to rapid and 
sustained expression of functional TRAIL protein resulting in apoptotic cell 
death in TRAIL positive tumours in vivo and in vitro (Voelkel-Johnson et al., 
2002). In addition, a completed phase I clinical trial of RAdTRAIL in patients 
with prostate cancer has demonstrated the ability of TRAIL to induce cell death 
in cancer cells  and tumour regression with minimal side effects (reviewed in  
Griffith et al., 2009). Moreover, modification and improvement of TRAIL gene 
delivery to increase efficacy are under investigation. For example through 
enhancement of infection by increasing distribution of adenovirus to infect 
every tumour cells (Seol et al., 2003, Hait and Yang, 2006). Modification of the 
mode of ligation may also increase the effect of TRAIL ligation on cell death 
and apoptosis induction.  Indeed previous studies in our laboratory on TNF 
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ligands particularly FasL and CD40L have confirmed the enhanced effect of 
membrane-bound forms of these ligands in inducing cell death (Elmetwali et 
al., 2010, Knox et al., 2003). On this basis, we sought to investigate modification 
of TRAIL ligation thorough retention of ligand on the cell membrane. 
 
3.2  : Results. 
A variety of methods exist for generation of recombinant adenoviruses (Bett et 
al., 1994, Young et al., 2006).  Here in this chapter we have used the AdEasy 
system (Quantum Biotechnology) using adenovirus vectors and methods as 
published by Chuan He and co-workers (He et al., 1998), due to the simplicity 
and the less time consumption compared to other published method. 
 
3.2.1 : Generation of a recombinant adenovirus expressing wild-type TRAIL. 
3.2.1.1 : PCR Amplification of full length TRAIL. 
To amplify the full-length TRAIL from a pcDNA3.1 vector encoding the full-
length TRAIL for cloning into the pShuttle CMV vector, an examination of the 
endonuclease restriction map of the full length of TRAIL was performed. As a 
result of this analysis, a couple of restriction sites (Sal1 and Xba1) were chosen 
for further PCR primers design, these  restriction sites do not exist in the TRAIL 
sequence but are in the multi cloning site (MCS) of the pShuttle CMV vector in 
an open reading frame downstream of the pShuttle  CMV promoter. Together 
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with a couple of specific forward and reverse primers (Forward primer :  TRAIL 
Sal1 F, 5’-A GTCGAC ATG-GCT-ATG-ATGG-AGG-TC-3’, Reverse primer: 
TRAIL Xba1 R, 5’ C- TCTAGA –TTA-GCC-AAC-TAA-AAA-GGC-CC-3’) 
artificially designed with  Sal1 and Xba1 (bold sequence) restriction sites were 
utilized to amplify the full-length TRAIL by PCR reaction under the following 
cycle conditions (93°C 5 mins (93°C 30 Sec, 58.1°C, 45 Sec, 72°C 2 mins) x 25, 
72°C, 5 mins), using a proof reading Taq polymerase (Roche) as described in 
section (2.1.1).  As shown in figure 3.1, analysis of the PCR reaction product on 
1% gel electrophoresis revealed an amplified fragment at the expected size of 
full-length TRAIL.   
To clone the amplified PCR TRAIL product into the Topo2.1 vector, the 
amplified PCR product was excised from the gel and  gel purified as described 
in section (2.1.3) then subjected to addition of A-overhangs (section 2.1.4). To 
clone the A-overhanged PCR product into the Topo2.1 vector, a TA cloning kit 
(Invitrogen) was utilized as previously described in section (2.1.6).  The ligated 
vector was  used to transform the E.coli TOPO 10F  competent cells, following 
selection of the transformants on ampicillin-containing LB- agar plates coated 
with 40µl of each x-Gal (40mg/ml) and IPTG (100mM), positive colonies were 
selected and miniprepped DNA was digested with Sal1 and Xba1 to confirm the 
cloning of the TRAIL into the Topo2.1 vector. To check whether any mutations 
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occurred during the cloning process, selected clones were sequenced which 
have confirmed  the absence of any mutations within  the TRAIL sequence. 
 
 
 
 
 
Figure 3.1: Agarose gel electrophoresis of the TRAIL PCR product. 
Five microlitres of the purified PCR TRAIL product was run in 1% agarose gel 
containing 0.2µg/ml EtBr. The amplified fragment runs at an expected size of 
the TRAIL sequence of 843bp.   
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3.2.1.2 : Cloning of full-length TRAIL into pShuttle CMV vector. 
Following confirmation of the TRAIL sequence cloned into Topo2.1 vector by 
Sal1 and Xba1 restriction digestion and sequence analysis, 2µg of Topo2.1TRAIL 
construct and 1µg of pShuttle CMV vector were digested with Sal1 and Xba1 
restriction endonucleases, which resulted in releasing the TRAIL fragment from 
the Topo2.1 vector and linearizing pShuttle CMV vector. TRAIL fragment and 
linearized pShuttle CMV vector were excised from 1% agarose gel and gel 
purified separately from gel by Qiagen gel extraction kit as described in section 
(2.1.3).  Following DNA purification, TRAIL DNA fragment was then ligated 
into Sal1 and Xba1 predigested and purified pShuttle CMV vector, using T4 
ligase reaction as described in section (2.1.7). Ligated pShuttle TRAIL vector 
was used to transform TOPO 10F competent cells, positive clones were selected 
on kanamycin (50µg/ml) containing LB-agar medium for further analysis with 
restriction digestion and sequencing. As shown in Figure 3.2, Sal1 and Xba1 
restriction digestion resulted in releasing a fragment at the expected TRAIL 
size, furthermore, sequence analysis of the selected pShuttle TRAIL clones 
revealed the right TRAIL sequence that has been inserted correctly in an open 
reading frame downstream of the CMV promoter of the pShuttle vector.. 
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Figure 3.2: Restriction digestion of miniprepped DNA empty pShuttle and 
pShuttlewt TRAIL constructs. 
100 ng of either pShuttle empty vector or pShuttle wtTRAIL construct were 
digested with Sal1 and Xba1 restriction enzymes, which resulted in releasing the 
wtTRAIL DNA fragment at an expected size of 843bp.  
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3.2.1.3 : Insertion of TRAIL into the pAdEasy-1 vector by homologues 
recombination. 
The pAdEasy-1 adenoviral plasmid contains all Ad5 sequences except 
nucleotides 1–3,533 (encompassing the E1 genes) and nucleotides 28,130–30,820 
(encompassing E3). The left arm of the pShuttle CMV vector contains the Ad5 
nucleotides 34,931-35,935. The right arm contains Ad5 nucleotides 3,534–5,790 
which mediate homologous recombination with the PAdEasy-1 vector in E.coli, 
plus inverted terminal repeat (ITR) and packaging signal sequences 
(nucleotides 1–480 of Ad5) required for viral production in mammalian cells.  
To insert the TRAIL sequence into the Adenoviral backbone, the pShuttle 
wtTRAIL construct was homologously recombined with PAdEasy-1 vector as 
described by Chuan He and co-workers (He et al., 1998). Typically, 1.0g of 
pShuttle wtTRAIL vector was linearized with PmeI, purified by 
phenol/chloroform extraction, and mixed with 0.1g of pAdEasy-1 in a total 
volume of 6l. The DNA mixture was used to transform 20l of 
electrocompetent E. coli BJ5183 cells by electroporation method. Transformed 
BJ5183 cells were then recovered in soc medium for 1 hour and plated onto LB-
agar medium containing 50g/ml kanamycin and incubated at 37°C until 
colonies showed up. The smaller colonies (which usually represented the 
recombinants) were picked up and grown in 2ml of L-Broth containing 50g/ml 
of kanamycin. Clones were first screened by analysing their supercoiled sizes 
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on agarose gels as shown in figure 3.3A, comparing them to pAdEasy-1 control 
vector. One of the selected clones was further examined by Pac1 restriction 
endonuclease digestion. As shown in Figure 3.3B, Pac1 restriction digestion 
results suggest that the homologous recombination has occurred in the desired 
orientation. This clone was designated as RAdwtTRAIL virus. 
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A                                                                     B 
 
 
Figure 3.3:   Agarose gel electrophoresis of constructed RAdwtTRAIL. 
A-500ng of miniprepped DNA of empty pAdeasy-1 vector, pShuttle wtTRAIL, 
PAdeasy wtTRAIL were run in 1% agarose gel electrophoresis containing 
0.2µg/ml EtBr. 
B-Pac1 restriction digestion of empty pAdeasy-1 vector, pShuttle wtTRAIL, 
PAdeasy wtTRAIL, restriction digestion products were run on 1% agarose gel 
electrophoresis containing 0.2µg/ml EtBr. 
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3.2.1.4 : Packaging of RAdwtTRAIL in HEK 293 cells. 
In order to generate an infective RAdwtTRAIL, RAdwtTRAIL vector construct 
was digested with Pac1 enzyme to expose the lift and the right inverted 
terminal repeats (ITR), the Pac1 digested product of RAdwtTRAIL construct 
was used to transfect HEK293 cells. HEK293 cells are E1 positive and express 
adenoviral proteins encoded by E1A and E1B genes that are required for 
replication of E1, E3-deleted adenoviral vectors, thus allowing the packaging 
and production of the adenovirus. RAdwtTRAIL-transfected HEK293 cells were 
monitored for 7 days until viral plaques appeared. Figure 3.4, demonstrates the 
several steps involved in generation of recombinant adenoviruses. 
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Figure 3.4: Illustrating diagram of the three different stages involved in 
adenoviral production. 
Three different stages are involved in adenovirus production: First stage 
involves cloning the gene of interest in pShuttle vector, second stage involves 
integration of the gene of interest with the adenoviral backbone by homologous 
recombination between the pShuttle construct and the adenoviral backbone 
vector, final stage involves viral packaging and production in HEK 293 cells. 
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3.2.2 : Verification of the expression of wtTRAIL from the constructed 
RAdwtTRAIL virus. 
To examine whether the generated RAdwtTRAIL virus expresses the TRAIL 
protein, HEK 293 cells which are E1-positive and therefore have the ability to 
support replication-deficient adenoviral vector propagation were infected with 
either RAdwtTRAIL or RAdMock (been previously generated in our Lab by Dr. 
Taha Elmitwalli viruses at 1 MOI or left un-infected as a negative control,  
Given that HEK 293 cells are TRAIL receptor positive cell line, cells were 
treated with the anti-apoptotic pan-caspase inhibitor z-VAD at a concentration 
of 20µM to protect cells from an expected TRAIL-induced cell death. Cells were 
incubated for 48 hours then lysed in situ and 100μg of total protein lysates were 
examined by western blotting analysis for TRAIL protein expression using goat 
polyclonal antibody raised against TRAIL C-terminus (C-19 Santa cruz 
biotechnology) region. As demonstrated in figure 4.5, TRAIL expression from 
RAdwtTRAIL-infected cells but not from RAdMock or uninfected control cells 
was detected. To ensure that equal amounts of total cell lysates were loaded, β-
actin was examined as well using monoclonal mouse anti-β-actin antibody. As 
seen in figure 3.5, β-actin expression was equal between samples. 
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Figure 3.5: Verification of TRAIL expression from the constructed RAdwtTRAIL 
adenovirus. 
HEK293 cells were infected with either RAdwtTRAIL or RAdMock viruses at 1 
MOI or left un-infected as a negative control for 48 hours then lysed in situ. 
100μg of total protein lysates were immunoblotted for TRAIL using goat 
polyclonal antibody raised against TRAIL C-terminus (C-19 Santa cruz 
biotechnology) region. β-actin was also examined to ensure equal loading 
between samples.  
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3.2.4 : An examination of the TRAIL receptors expression in selected panel of 
carcinomas. 
To test the direct effect of the constructed RAdwtTRAIL adenovirus on TRAIL 
receptor-positive carcinomas, we examined the expression of TRAIL receptor 1 
and 2 at the level of both mRNA and protein in a panel of carcinoma cell lines 
including the cervical cell line Hela, the hepatic cell line HepG2 and the ovarian 
cell lines SKOV-3, OVCAR-3 and A2780. Cell lines were grown and mRNA was 
extracted and subjected to cDNA synthesis as described in section (2.1.12), 
Following cDNA synthesis, RT-PCR reaction was performed utilizing specific 
TRAIL-R1 and TRAIL-R2 forward and reverse primers and 1µl of cDNA as a 
template.  As shown in figure 3.6A, adequate levels TRAIL-R1 and TRAIL-R2 
were detected in all examined cell lines with the only exception of TRAIL-R1 in 
the ovarian carcinoma A2780 cell line which was not detected. To examine 
whether, similar pattern of expression exists at the level of protein, protein 
samples were collected from these cell lines and examined by western blot 
analysis using specific antibodies against TRAIL-R1 and TRAIL-R2 proteins. As 
shown in figure 3.6B, higher levels of TRAIL-R1 and TRAIL-R2 expression were 
detected in  Hela, HepG2 and OVCAR-3 cells, β-actin was also examined to 
ensure equal loading between samples. 
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Figure 3.6: Expression of TRAIL-R1 and TRAIL-R2.  
A-1µg of total RNA was subjected to cDNA synthesis by reverse transcription 
method using the retroscript cDNA kit (Invitrogen Cat AM1710). One microliter 
of total cDNA was then used as a template for amplification of TRAIL-R1 and 
TRAIL-R2 using specific primers for each receptor, GAPDH was also amplified 
to ensure equal amount of cDNA input. 
B-100µg of total protein lysates were examined for TRAIL-R1 and TRAIL-R2 
expression using specific antibodies raised against TRAIL-R1 and TRAIL-R2. β-
actin was also examined as a loading control. 
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3.2.5 An examination of the direct effect of RAdwtTRAIL on TRAIL receptor-
positive carcinomas  
To examine the effect of wild-type TRAIL on carcinomas cell viability, a panel 
of TRAILR1 and 2-positive cell lines including the cervical cell line Hela cells, 
the hepatic cell line HepG2 and the ovarian cell lines OVCAR-3 and A2780 cells 
which expresses lower levels of TRAILR1 and 2 were infected with either 
RAdwtTRAIL, RAdMock or left untreated as a negative control at the indicated 
multiplicities of infection (MOI) for 48 hours. Cell viability was then assessed by 
WST-1 assay as described in section 2.2.5.1. As shown in figure 3.7, different cell 
lines exhibited different degrees of sensitivity to the RAdwtTRAIL with the 
greatest sensitivity observed in  Hela, HepG2 and OVCAR-3 cells, where lower 
sensitivity was noticed with the A2780. RAdwtTRAIL-induced cell viability 
reduction was enhanced by increasing the MOI, whereas no difference was 
noticed with similar MOI of RAdMock infection.  A2780 cells failed to response 
to RAdwtTRAIL-infection, which is likely attributed to the level of the TRAIL 
receptor expression in these cells. To exclude the possibility of reduced 
adenovirus infectability in A2780 cells, we tested the infectability of A2780 cell 
using a RAdGFP mock vector. As shown in figure 3.8, 100% infection in A2780 
cells was obtained at 150MOI. 
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Figure 3.7:  Direct effect of RAdwtTRAIL on cell viability. 
Hepatocelluler carcinoma HepG2 cell line, ovarian carcinoma cell line OVCAR-
3, cervical carcinoma cell line Hela and A2780 were infected with the indicated 
MOI of RAdwtTRAIL or RAdMock or left without infection for 48 hours. Cell 
viability was assessed by WST-1ssay. Results represent the mean of triplet 
samples ±SD. 
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A) 
 
B) 
 
Figure 3.8: A2780 cell line infectability rate by RAdMock GFP. 
A) A2780 ovarian carcinoma cell line were infected with RAd Mock GFP at 
different MOI (10,50,100,150,and 300), GFP expression was visualized 
under UV microscope. 
B) RAd Mock GFP-infected cells were counted and expressed as percentage 
to uninfected cells. 
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3.2.6 : An examination of the cleavage of TRAIL from RAdwtTRAIL in 
RAdwtTRAIL-infected cells. 
 The majority of TNF ligands are naturally expressed as a membrane bound-
structure and upon expression they are naturally cleaved from the membrane 
by the action of specific group of proteases belonging to the family of 
metalloproteinases (MMPs). To examine whether TRAIL protein expressed 
from RAdwtTRAIL is also subject to cleavage from membrane by the action of 
MMPs, the cervical carcinoma Hela cells were infected with 100MOI of either 
RAdwtTRAIL or RAdMock or left uninfected as a negative control.  Samples 
were collected from the culture media 24 and 48 hours post-infection for 
sTRAIL measurement utilising a sTRAIL ELISA assay kit (R&D Biosystems 
MAB3751). As shown in figure 3.9, a significant quantity of sTRAIL was 
detected within RAdwtTRAIL-infected cells and the amount of sTRAIL 
detected increased over time. However, no sTRAIL was detected in culture 
media collected from either RAdMock-infected cells or uninfected control cells, 
indicating that wtTRAIL protein is also subject to cleavage from cell membrane. 
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Figure 3.9: TRAIL cleavage from RAdwtTRAIL-infected Hela cells. 
Hela cells were infected with 100 MOI of either RAdMock or RAdwtTRAIL or 
left uninfected as a negative control.  Samples were collected from the culture 
media 24 and 48 hours post-infection for sTRAIL measurement. Results are 
mean of triplet samples ±SD 
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3.2.7 : An examination of the direct effect of matrix metalloproteinase 
inhibitors (MMPIs) on TRAIL cleavage from RAdwtTRAIL 
adenovirus. 
Given that TRAIL expressed from RAdwtTRAIL adenovirus in RAdwtTRAIL-
infected Hela cells was also subject to cleavage from the membrane, we next 
tested whether TRAIL cleavage is mediated by the action of the MMPs family. 
Thus the human cervical carcinoma Hela cells were infected with 100MOI of 
either RAd Mock or RAdwtTRAIL or left without infection as a negative control 
or treated with 100ng/ml of sTRAIL. Cells were either treated with 30µM of 
MMPI II (Calbiochem, cat 444247), a potent, reversible inhibitor of a broad-
range of a number of MMPs at a concentration of 30µM (previously defined as 
the maximum tolerated non-toxic dose) or left without treatment for a further 
48 hours. Samples were collected from the culture media 48 hours post-
infection for sTRAIL measurement. Furthermore, culture media were replaced 
with a fresh medium and cell viability assessed by WST-1 assay reagent.  As 
shown in figure 3.10, MMP inhibitor was capable of blocking the cleavage of 
soluble TRAIL in RAdwtTRAIL-infected Hela cells at a 30µM concentration. 
This concentration was well-tolerated by cells, with no cell viability reduction 
observed in Hela control cells. Interestingly, blocking of cleavage of TRAIL in 
RAdwtTRAIL-infected cells exhibited a significant cell viability reduction 
compared to MMPI-untreated cells, indicating that a membrane bound TRAIL 
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structure is more potent inducer of cell viability reduction compared to wild-
type TRAIL which is subject to cleavage from the membrane. Moreover, MMPI 
treatment by itself does not sensitize cells to sTRAIL treatment or any of the 
adenoviral proteins, as the MMPI did not induce any cell viability reduction 
with RAdMock-infected cells or sTRAIL-treated uninfected cells. 
  
Chapter 3                                                                                         Results 
102 
A) 
 
 
 
 
 
 
B) 
 
Figure 3.10: Effect of MMPI II on sTRAIL cleavage from RAdwtTRAIL in 
RAdwtTRAIL-infected Hela cells. 
Hela cells infected with 100 MOI of RAdMock, RAdwtTRAIL or left uninfected 
as a negative control or treated with 100ng/ml of sTRAIL were treated with 
30µM of MMPI II or left untreated were grown for 48 hours. 
A-Culture media samples were collected from each well except sTRAIL- treated 
cells for sTRAIL ELISA assessment. Results are mean of triplet samples± SD 
B-Cell viability was assessed by WST-1 assay and the results are the mean of 
triplet samples± SD. 
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3.2.8 : An attempts to identify the MMPs-targeted cleavage site in wt TRAIL.  
The results described in this chapter, have clearly demonstrated that inhibition 
of sTRAIL cleavage from membrane by the effect of MMPI II enhances the 
RAdwtTRAIL-induced cell viability reduction in RAdwtTRAIL-infected Hela 
cells,  therefore, highlighting the potential effect of membrane bound TRAIL in  
inducing cell viability reduction and apoptotic induction in TRAIL receptors-
positive carcinomas compared with wt TRAIL.  
Previous work from our laboratory has shown that FasL lacking the 128EKQI131 
cleavage site is more potent in cell death induction. Given that TNF ligands 
possess a high percentage of sequence homology, a CD40L cleavage site  
110SFEMQKG116 was also identified by sequence alignment between FasL and 
CD40L (Elmetwali et al., 2010a, 2010b, Knox et al., 2003, Milner et al., 2002). 
Therefore, a possible alignment between FasL, CD40L and TRAIL may provide 
some information about the possible TRAIL cleavage site. Therefore, sequence 
alignment between the published FasL, CD40L, cleavage sites and TRAIL was 
performed. As shown in figure 3.11, we have identified an  105EKQQ108     site 
(bold letters) similar to Fas L cleavage site 128EKQI131, so we next aimed to  
generate a TRAIL mutant that lacks these four amino acids, as well as another 
TRAIL mutant that lacks the sequence from 105-115aa in case if the EKQQ-
deleted TRAIL sequence was still subject to TRAIL cleavage from membrane. 
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Figure 3. 11: Amino acid alignment of FasL, CD40L and TRAIL. 
Sequence alignment identified a possible motif in extracellular domain of 
TRAIL which is identical to three amino acids in the FasL cleavage site. Deleted 
sequence in the TRAIL mutant 1 (TRAIL mt1) and mutant 2 (TRAIL mt2) are 
highlighted in red.  
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3.2.9 : Generation of pShuttleCMV constructs expressing EKQQ (105-108aa) 
and EKQQHISPLV (105-115aa)- deleted TRAIL proteins. 
To generate two TRAIL mutants (mutant 1; mt1 and mutant 2; mt2) with 
deletion mutation from 105-108aa and 105-115aa respectively,  we utilised the 
quick change site-directed mutagenesis (SDM) reagent (Stratgene) as described 
in section (2.1.17).  For 105EKQQ108 deleted TRAIL sequence, the forward 
TRAILde105-108F, 5’-GGA AAC CAT TTC TAC AGT TCA AAA TAT TTC TCC 
CCT AGT G-3’ and the reverse primer TRAILde105-108R, 5’CAC TAG GGG 
AGA AAT ATT TTG AAC TGT AGA AAT GGT TTC C-3’ were used. For the 
deletion spanning from 105EKQQHISPLV115, the forward primer TRAILde105-
115F, 5’-GAG GAA ACC ATT TCT ACA GTT CAA GAA AGA GGT CCT CAG 
AGA GTA GCA GC-3’ and the reverse primer TRAILde109-115R, 5’-CTC CTT 
TGG TAA AGA TGT CAA GTT CTT TCT CCA AGA GTC TCT CAT CGT CG-
3’ were used. Obtained PCR reaction was then used to transform XL1-Blue 
supercompetent cells provided by the SDM producer. The sequence of the 
TRAIL mutants was then confirmed within the obtained miniprepped DNA 
clones by restriction digestion with Sal1 and Xba1 restriction endonucleases and 
analysis on low present gel electrophoresis (0.5%). As shown in Figure 3.12, a 
slight difference was observed with the size of the released TRAIL DNA 
fragments compared to wild-type TRAIL, as expected from the deletion 
mutation. To confirm the presence of the deletion mutation, the selected clones 
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were sequenced and sequence analysis confirmed the presence of the deletion 
mutations within the majority of the selected clones. 
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Figure 3.12: Sal 1 and Xba1 restriction digestion of the pShuttle -CMV TRAIL 
constructs. 
Half microgram of the selected Miniprepped DNA was digested with Sal1 and 
Xba1 restriction endonucleases, the resultant restriction digestion products were 
resolved on 0.5% agarsoe gel containing 0.2µg/ml ethidium bromide.   
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3.2.10 : An examination of the cleavage of sTRAIL from the constructed 
pShuttle TRAIL mutants. 
To examine whether the 105EKQQ108 or the 105 EKQQHISPLV115 deletion mutation 
in the TRAIL mutant 1 and 2 respectively were capable of blocking the cleavage 
of the TRAIL from the membrane, HEK 293 cells were transfected with 1µg 
DNA of either pShuttle wtTRAIL or pShuttle TRAILmt1 or pShuttle TRAILmt2 
or pShuttle CMV or left untransfected as a negative control.  Samples were 
collected from the culture media 48 hours post-transfection for sTRAIL 
assessment. As shown in figure 3.13, a significant quantity of sTRAIL was 
detected within pShuttle wtTRAIL, pShuttle TRAILmt1, and pShuttle 
TRAILmt2 transfected cells and the quantity of sTRAIL released into the culture 
medium was similar, indicating that the deletion mutations were not able to 
block the MMP-mediated cleavage of TRAIL. 
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Figure 3.13: An Examination of the TRAIL cleavage from constructed pShuttle 
CMVTRAIL mutants. 
HEK 293 cells were transfected with 1µg DNA pShuttle CMV or pShuttle 
wtTRAIL or pShuttle TRAILmt1 or pShuttleTRAILmt2 or left non transfected as 
a negative control. Samples were collected from the culture media 48 hours 
post-transfection for sTRAIL measurement. Results are mean of triplet samples± 
SD 
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3.3 : Discussion. 
The tumours necrosis factor (TNF) cytokine superfamily plays a crucial role in 
immune regulation by modulating lymphocyte proliferation and apoptosis 
(Cancro and Smith, 2003). TNF cytokine superfamily ligands have also been 
implicated in the induction of tumour cell death induction and apoptosis 
depending on the mode of ligation.  The effect of membrane bound TNF ligand 
structures compared with wild-type or soluble forms are well characterized in 
both of CD40 and Fas ligands (Elmetwali et al., 2010, Georgopoulos et al., 2006, 
Knox et al., 2003, Milner et al., 2002). TNF ligands are naturally expressed as a 
membrane bound ligands that are subject to cleavage from the membrane by 
the effect of members of a group of proteases belong to the matrix 
metalloprotenases (MMPs) family.  
 To examine whether TRAIL has the same pattern as CD40L and FasL we 
successfully generated a replication-deficient adenovirus (RAd) expressing 
wild-type TRAIL (RAdwtTRAIL) protein. The expression of TRAIL protein was 
confirmed as HEK 293 cells infected with RAdwtTRAIL but not RAdMock or 
uninfected control cells showed a significant detectable level of TRAIL protein 
as shown by western blot analysis, confirming the successful generation of 
RAdwtTRAIL virus.  RAdwtTRAIL adenovirus was found to reduce cell 
viability in TRAIL receptor 1 and 2- positive carcinomas (Hela, OVCAR-3 and 
HepG2) but not in A2780 cells where the levels of TRAIL-R1 and TRAIL-R2 
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were confirmed to be very low as shown by western blot analysis have also 
confirmed that wild-type TRAIL is subject to cleavage from membrane and that 
such cleavage is mediated by the action of MMPs. Inhibition of MMP activity 
resulted in enhanced RAdwtTRAIL-induced cell viability reduction and this 
was mainly attributed to the blocking of the cleavage of the TRAIL from 
membrane, since RAdMock-infected Hela cells treated with MMPI didn’t 
exhibit any reduction in cell viability compared to MMPI untreated RAdMock-
infected cells, thus excluding the possibility of any synergy between the MMPI 
and the expressed adenoviral proteins. Moreover, MMPI treatment didn’t 
sensitize Hela cells to sTRAIL treatment, suggesting that blocking of the 
cleavage of TRAIL from membrane by the action of MMPI is the only factor that 
enhanced the RAdwtTRAIL-induced cell viability reduction in RAdwtTRAIL-
infected Hela cells.  Given that TNF ligands possess higher sequence homology 
between each other, it was important to examine whether a similar MMP 
cleavage site to that exist in FasL and CD40L also exist in TRAIL sequence, 
sequence alignment between CD40L, FasL and TRAIL has revealed a possible 
cleavage site in the TRAIL sequence (105EKQQ108), therefore we attempted to 
generate TRAIL mutants with the identified sequence and with further 
sequence deletion spanning the 105 EKQQHISPLV115 motif. However the 
sequence deletion of  105EKQQ108 or the 105 EKQQHISPLV115  in the TRAIL 
sequence couldn’t block the cleavage of TRAIL from membrane in pShuttle 
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TRAIL mutant 1 or 2 (mt1 or mt2)-transfected HEK293 cells as sTRAIL was still 
detected in those cells as confirmed by sTRAIL ELISA assessment. This could be 
explained by MMPs targeting TRAIL sequences at different or multiple 
cleavage sites such that more deletion mutations may be needed to block the 
cleavage from membrane. Since the mutations (105EKQQ108 or the 105 
EKQQHISPLV115) in TRAIL failed to block the cleavage of the TRAIL 
membrane, other approaches for generating a membrane bound TRAIL were 
explored. 
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CHAPTER 4 
GENERATION OF REPLICATION-DEFICIENT ADENOVIRUS 
(RAd) EXPRESSING A MEMBERANE-BOUND CD40LTRAIL 
FUSION PROTEIN 
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4.1 : Introduction. 
Previous results from our lab and others have demonstrated the efficacy of 
membrane-bound CD40L and FasL in cell death induction and apoptosis 
compared to soluble or wild-type counterparts. Previous results in chapter 3 
have clearly demonstrated the direct effect of MMPI II inhibitor on blocking 
TRAIL cleavage from membrane in RAdwtTRAIL-infected cells, and that 
blocking of the cleavage of TRAIL by the MMPI II inhibitor resulted in 
enhanced RAdwtTRAIL-induced cell viability reduction, suggesting that a 
membrane-bound TRAIL is more potent in cell death induction than wild-type 
or soluble TRAIL. Given that both CD40L and TRAIL belong to the same family 
and they share a significant homology (25-30%) (Pitti et al., 1996), and  deletion 
mutations in the TRAIL sequence identified by sequence alignment between 
TRAIL sequence and the published FasL and CD40L membrane cleavage sites 
were unable to block the cleavage of TRAIL from membrane in pShuttle TRAIL 
mutant 1 and 2 compared to pShuttle TRAIL wt-transfected HEK 293 cells,  we 
thought of generating a hybrid fusion between the CD40L N-terminal domain  
(1-324bp) upstream of the CD40L cleavage site (324-348bp) and the C-terminal 
domain of TRAIL ligand (340-846bp, containing the TRAIL active site). This 
hybrid fusion of CD40LTRAIL is expected to be a membrane bound molecule 
that resists the MMPs-mediated TRAIL cleavage at the cell surface due to the 
lack of either CD40L or TRAIL cleavage sites in the CD40LTRAIL hybrid fusion.  
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Here in this chapter we will describe the construction of CD40LTRAIL hybrid 
fusion and a replication-deficient adenoviral vector expressing this fusion 
protein, also we will investigate the direct effect of this virus on cell viability 
reduction  compared to the RAdwtTRAIL virus constructed in chapter 3.   
 
4.2 : Results. 
4.2.1 : Generation of Adenoviral vector expressing the CD40LTRAIL fusion 
protein. 
4.2.1.1 : Generation of CD40L N-terminal fragment (1-224bp). 
To amplify a CD40L fragment (1-324bp) encoding DNA, a pCLneoCD40L 
construct together with a couple of forward CD40L1Sal1F, 5’-AGTC GAC ATG 
ATC GAA ACA TAC AAC CA-3’ and reverse primers CD40L324R, 5-TTC TTT 
CTT CGT CTC CTC TTT GTT-3’ were used under the following the PCR 
condition (93°C 5 mins (93°C 30 Sec, 58.1°C, 45 Sec, 72°C 2 mins) x 25, 72°C, 5 
mins). The PCR product was gel purified using a gel extraction purification kit 
(Quiagen) and the DNA was eluted in 30µL deionized distilled water as 
described in section 2.1.3. Five microlitres of the purified PCR product was run 
in 1% gel electrophoresis (Section 2.1.2) as shown in figure 4.1. 
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Figure 4.1: Analysis of PCR amplified CD40L N-terminal (1-324bp).  
Five microlitres of the purified PCR product was run in 1% agarose gel 
containing 0.2µg/ml EtBr. The amplified fragment runs at an expected size of 
(324bp). M refer to the DNA ladder, 1 refers to the amplified CD40L fragment 
(1-324bp). 
  
M     1 
 
Chapter 4              Results 
 117 
4.2.1.2 : Generation of the TRAIL C-terminus fragment. 
To amplify the C-terminus TRAIL sequence (340-846bp), a pShuttle wtTRAIL 
construct, was used together with a couple of forward CD40L324TRAIL340F, 5’-t 
ata atg tta aac aaa gag gag acg aag aaa gaa GTG AGA GAA AGA GGT CCT 
CAG AGA GTA-3 and reverse primer TRAIL846 HindIIIR, 5’-A AA GCT TTT 
AGC CAA CTA AAA AGG CC-3’  were used, the CD40L324TRAIL340F primer 
was designed such that CD40L sequence (290-324bp red color) would be 
flanked to the amplified TRAIL fragment. The PCR was performed under the 
following conditions  93°C 5 mins (93°C 30 Sec, 58.4°C, 45 Sec, 72°C 2 mins) x 
25, 72°C, 5 mins. The PCR product was gel purified using a gel extraction 
purification kit (Quiagen) and the DNA was eluted in 30µL deionized distilled 
water. Five microlitres of the purified PCR product was run in 1% gel 
electrophoresis as shown in figure 4.2. 
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Figure 4.2: Analysis of PCR amplified TRAIL C-terminal (340-846bp).  
Five microlitres of the purified PCR product was run in 1% agarose gel 
containing 0.2µg/ml EtBr. The amplified fragment runs at an expected size of 
(506bp). 
  
M     1 
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4.2.1.3 : PCR amplification of the CD40LTRAIL fusion. 
To combine the above generated CD40L and TRAIL fragments, 100pg of the 
amplified CD40L and TRAIL fragments were mixed together and used as a 
template for the following PCR reaction utilizing the forward primer 
CD40L1Sal1F 5’-AGTC GAC ATG ATC GAA ACA TAC AAC CA-3’ and the 
reverse primer TRAIL846 HindIIIR 5’-A AA GCT TTT AGC CAA CTA AAA 
AGG CC-3’. As shown in figure 4.3, analysis of the PCR reaction product on 1% 
gel electrophoresis revealed an amplified fusion of Cd40L-TRAIL at the 
expected size. 
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Figure 4.3:   Agarose gel electrophoresis of the PCR product of CD40LTRAIL 
fusion. 
Five microlitres of the purified CD40LTRAIL product was run in 1% agarose gel 
containing 0.2µg/ml EtBr.  M refers to the DNA ladder, 1 refers to the amplified 
CD40LTRAIL fragment which runs at an expected size of the TRAIL of 831bp. 
  
M          1 
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4.2.1.4 : Cloning of CD40LTRAIL into pShuttle CMV vector. 
To clone the amplified PCR CD40LTRAIL fusion product into the pShuttle 
CMV vector, CD40LTRAIL fusion was first cloned into the Topo2.1 vector. The 
amplified PCR product was excised from the gel and  gel purified as described 
in section 2.1.3 then subjected to addition of A-overhangs (Section 2.1.4). To 
clone the A-overhanged PCR product into the Topo2.1 vector, a TA cloning kit 
(Invitrogen) was utilized as previously described in section 2.1.6. Miniprepped 
DNA was then digested with SalI and HindIII enzymes to release the 
CD40LTRAIL fusion. The purified DNA fragment was then ligated into 
SalI/HindIII predigested and purified pShuttle CMV vector. The sequence of 
CD40LTRAIL fusion was then confirmed by sequence analysis and restriction 
digestions as in figure 4.4.   
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Figure 4.4: Analysis of the pShuttle CMV CD40LTRAIL minipreped DNA. 
Predigested pShuttle CMVCD40LTRAIL with SalI and HindIII miniprepped 
were analysed using 1% agrose gel electrophoresis. M refers to DNA ladder. 
Lane 1 refers to empty vector, where lane 2 refers to pShuttle-
CMVCD40LTRAIL construct.   
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4.2.2 : Generation of recombinant adenoviral vector expressing the 
CD40LTRAIL fusion.   
Using 1.0g of PmeI, pre-digested and phenol/chloroform purified pShuttle 
CMVCD40LTRAIL mixed with 0.1g of pAdEasy-1 in a total volume of 6l, the 
DNA mixture was used to transform 20l of electrocompetent E. coli BJ5183 
cells by electroporation. Positive clones were first screened by analyzing their 
supercoiled sizes on agarose gel, comparing them to pAdEasy-1 control. Those 
clones that had inserts were further examined by Pac1 restriction endonuclease 
digestion (Figure 4.5). Once confirmed, supercoiled plasmid DNA was 
transformed into TOPO 10F chemically competent cells for large-scale DNA 
amplification. Purified plasmid DNA was digested with PacI and used to 
transfect HEK 293. Transfected HEK 293 cells allowed the packaging and 
production of adenovirus as previously described in section 3.2.1.4. The 
packaged adenovirus was designated as RAdCD40LTRAIL virus. 
 
 
 
 
Chapter 4              Results 
 124 
 
 
 
Figure 4.5: Restriction digestion of RAdCD40TRAIL recombinant minipreped 
DNA.  
Miniprepped RAdCD40TRAIL recombinant DNA was digested with Pac I and 
analysed using 1% agarose gel electrophoresis. M refers to DNA ladder. Lane 1 
refers to empty pAdEasy vector, Lane 2 and 5 refer to the right clones with 
successful integration of the pShuttle CMV CD40LTRAIL into the adenoviral 
pAdEasy vector backbone, and lane 3 refers to pShuttle CMV CD40LTRAIL 
construct, where lane 4 refers to RAdCD40TRAIL clone where the homologues 
recombination occurred in wrong orientation. 
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4.2.3 : Verification of the expression of CD40LTRAIL fusion from 
RAdCD40LTRAIL virus. 
To examine whether the generated RAdCD40LTRAIL virus express the 
CD40LTRAIL fusion, bladder carcinoma cells EJ were infected with either 
RAdwtTRAIL or RAdCD40LTRAIL or  RAdMock at 100 MOI or left un-infected 
as a negative control. Cells were incubated for 36 hours then lysed in situ and 
60μg of total protein lysates were examined by western blotting analysis for 
TRAIL protein expression. As demonstrated in figure 4.6, TRAIL expression 
from RAdwtTRAIL and RAdCD40LTRAIL-infected cells but not from 
RAdMock or uninfected control cells was detected. To ensure that equal 
amounts of total cell lysates were loaded, β-actin was examined as well using 
monoclonal mouse anti-β-actin antibody. As seen in figure 4.6, β-actin 
expression was equal between samples. 
. 
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Figure 4.6: Verification the expression of the wild-type TRAIL and CD40L-
TRAIL chimera from the generated viruses. 
EJ cells infected with 100 MOI of RAd wtTRAIL (AdL) or RAdCD40LTRAIL 
(AdncL) RAdMock (AdM) or left uninfected as a negative control were grown 
for 36h, cells were lysed in situ and 60µg of total protein lysates were examined 
for TRAIL expression using specific antibody raised against TRAIL C-terminus 
domain. β-actin was also examined as a loading control.  
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4.2.4 :  Verification that CD40LTRAIL is not cleaved from cell surface into 
soluble TRAIL in RAdCD40LTRAIL-infected EJ cells 
To examine whether CD40LTRAIL fusion protein expressed from 
RAdCD40LTRAIL is not cleaved from the cell membrane, bladder carcinoma 
cells EJ were infected with 100 MOI of either RAdCD40LTRAIL or 
RAdwtTRAIL or RAdMock or left uninfected as a negative control.  Samples 
were collected from the culture media 24 and 48 hours post-infection for 
sTRAIL measurement utilising a sTRAIL ELISA assay kit. As shown in figure 
4.7, a significant quantity of sTRAIL was detected within infected cells in a time 
dependant manner. However, no sTRAIL was detected in culture media 
collected from either RAdMock or the RAdCD40LTRAIL-infected cells 
indicating that CD40LTRAIL fusion is maintained at the cell surface. 
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Figure 4.7: Confirmation of the retention of TRAIL expression by 
RAdCD40LTRAIL at the cell surface. 
EJ cells were infected with 100 MOI of either RAdCD40LTRAIL or 
RAdwtTRAIL or RAdMock or left uninfected as a negative control. Samples 
were collected from the culture media 24 and 48 hours post-infection for 
sTRAIL measurement. Results are mean of triplet samples ±SD. 
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4.3 : Discussion. 
Results reported in Chapter 3and 4 investigating blocking the cleavage of 
TRAIL from cell surface in RAdwtTRAIL-infected cells using the MMPI II 
inhibitor clearly demonstrated the effect of membrane-bound TRAIL in cell 
death induction and apoptosis in TRAIL receptor 1 and 2 positive cells.   
To generate a TRAIL mutant resistant to cleavage from the membrane, several 
attempts to identify the TRAIL cleavage site based on amino acid sequence 
alignment with the published FasL and CD40L cleavage site were performed, 
using the mutagenesis technique we have generated different mutants of 
TRAIL, however soluble TRAIL (sTRAIL) was always detected in culture media 
samples collected from cells transfected with these mutants. Therefore, we 
considered other approaches to generate a membrane-bound TRAIL mutant 
that can resist the cleavage from the cell surface whilst at the same time 
maintaining all the biological activity of TRAIL protein. Given that both CD40L 
and TRAIL belong to the same family and they share a significant homology 
(25-30%), raised the idea of making a hybrid fusion between CD40L and TRAIL. 
Therefore, a CD40L N-terminal region lacking the cleavage site (1-324bp) would 
possibly drive the expression of the active TRAIL ligand fragment (340-846bp, 
containing the TRAIL active site) at the cell membrane. To test this hypothesis, 
the CD40LTRAIL fusion was generated by polymerase chain reaction (PCR) 
technique, and the generated fusion sequence was successfully cloned into the 
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pShuttle vector in frame with the CMV promoter. Following Sal1 and HindIII 
restriction and sequencing analysis confirmation of the constructed pShuttle-
CMV CD40LTRAIL, we constructed an adenovirus vector that expressed the 
CD40LTRAIL fusion. The expression of the CD40LTRAIL fusion from the 
RAdCD40LTRAIL virus was then confirmed by western blotting analysis in 
bladder carcinoma EJ cells.  Furthermore, CD40LTRAIL protein expressed from 
RAdCD40LTRAIL is maintained at the cell surface and is resistant to the 
cleavage from membrane by the action of the MMPs since RAdCD40LTRAIL-
infected cells failed to release any soluble TRAIL into the culture medium 
compared with RAd expressing wild-type TRAIL. RAdCD40LTRAIL was also 
more potent in cell viability reduction than either RAdwtTRAIL or the sTRAIL 
as RAdCD40LTRAIL exhibited more cell viability reduction compared to other 
forms of TRAIL. 
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CHAPTER 5 
AN EXAMINATION OF THE DIRECT EFFECT OF 
RADCD40LTRAIL ALONE OR IN COMBINATION WITH 
CHEMOTHERAPUITIC DRUGS ON CELL VIABILITY 
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5.1 : Introduction. 
Results in chapter 3 and 4 have clearly demonstrated the direct effect of MMPI 
II inhibitor on blocking TRAIL cleavage from membrane in RAdwtTRAIL-
infected cells, and that blocking of the cleavage of TRAIL by the MMPI II 
inhibitor resulted in enhanced RAdwtTRAIL-induced cell viability reduction, 
suggesting that a membrane-bound TRAIL is more potent in cell death 
induction than wild-type or soluble TRAIL. Following successful generation of 
RAdCD40LTRAIL virus (chapter 4) and the confirmation of retention of the 
fusion protein at the cell surface,  here in this chapter we thought of 
investigating the direct effect of RAdwtTRAIL and RAdCD40LTRAIL either 
alone or in combination with cytotoxic drugs on TRAIL receptors positive 
carcinomas. 
 
5.2  : Results. 
5.2.1 : Effect of RAdCD40LTRAIL on TRAIL receptor-positive carcinomas 
compared to wild-type TRAIL ligands. 
To examine the  direct effect of membrane-bound TRAIL on carcinomas cell 
viability, a panel of TRAILR1 and 2-positive carcinomas including Hela, 
HepG2, A2780, OVCAR-3 and EJ cells were infected with either 
RAdCD40LTRAIL, RAdwtTRAIL, RAdMock or left uninfected as a negative 
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control at the indicated of MOI. As shown in figure 5.1, different cell lines 
exhibited different degrees of sensitivity to the CD40LTRAIL fusion compared 
to the wild-type TRAIL with the greatest sensitivity to the CD40LTRAIL fusion 
observed in HepG2, Hela and OVCAR-3 cells, where lower sensitivity was 
noticed with the bladder carcinoma EJ, and the ovarian carcinoma A2780 cells. 
Obtained results showed that RAdCD40LTRAIL induced greater cell viability 
reduction compared to RAdwtTRAIL or RAdMock-infected cells where no cell 
viability reduction were detected as shown in figure 5.1.  
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Figure 5.1: Effect of RAdwtTRAIL and RAdCD40LTRAIL on Cell Viability. 
Hepatocelluler carcinoma HepG2 cell line, Cervical cell carcinoma Hela, 
ovarian carcinoma cell lines A2780 and OVCAR-3 and the bladder carcinoma EJ 
cells were infected with the indicated MOI of RAdwtTRAIL or 
RAdCD40LTRAIL or RAdMock or left without infection for 48 hours. Cell 
viability was assessed by WST-1ssay. Results represent the mean of triplet 
samples ±SD. 
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5.2.2 : RAdCD40LTRAIL-induced cell viability reduction is attributed to 
apoptosis induction. 
To examine whether RAdCD40LTRAIL-induced cell viability reduction is 
attributed to apoptosis induction, Hela cells were infected with RAdwtTRAIL 
or RAdCD40LTRAIL or RAdMock at 100 MOI or let uninfected as negative 
control or treated with 100ng/ml sTRAIL, cells were either treated with the pan-
caspases inhibitor zVAD (Calbiochem) at a concentration of 30µM or left 
untreated as a negative control and seeded at a density of 6000 cells/100µl/well 
in 96 well microplate for 28 hours then assessed for caspase 3/7 activity as a 
marker for apoptotic  cell induction, utilizing the Caspase-Glo 3/7 assay reagent 
(Promega Cat, G8091) according the manufacturer’s instructions. As shown in 
figure 5.2,   RAdCD40LTRAIL-infected Hela Cells exhibited higher caspase 3/7 
activity compared to RAdwtTRAIL-infected cells, where no activity was 
detected in either RAdMock or sTRAIL-treated or untreated control cells, 
indicating that RAdCD40TRAIL-induced cell viability reduction is mainly due 
to an apoptotic cell induction. Furthermore, the pan-caspase inhibitor zVAD 
treatment resulted in abolishing the RAdCD40LTRAIL-induced caspase 3/7 
activity highlighting the specificity of the used assay.  
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Figure 5.2: Caspase 3/7 activity in RAdCD40LTRAIL-infected Hela cells.  
The cervical carcinoma cell line Hela cells were either infected with RAdMock 
(AdM), RAdwtTRAIL (AdL) or RAdCD40LTRAIL (AdnL) 1t 100 MOI or left 
uninfected or treated with recombinant soluble TRAIL at 100ng/ml (sTRAIL), 
were treated with or without the pan-caspase inhibitor zVAD at a concentration 
of 30µM and seeded at a density of 6000 cells/100µl/well in 96 well microplate 
for 28 hours. Caspase 3/7 activity was then assessed utilizing the Caspase-Glo 
3/7 Assay reagent according to the manufacturer’s instructions (Promega, cat 
G8091). Results represents mean of triplet samples ± SD. 
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5.2.3 : An in vitro examination of synergy between RAd expressing either 
wild-type TRAIL or CD40LTRAIL fusion proteins. 
Results in this chapter and chapter 3 and 4 have demonstrated the direct 
inhibitory effect of RAd vectors expressing either wild-type TRAIL or 
CD40LTRAIL fusion proteins on cell viability in TRAIL receptor 1 and 2-
positive carcinomas. Given that chemotherapeutic drugs can act in synergy 
with other members of the TNF family ligands, the possibility of enhancing the 
TRAIL-mediated growth inhibition by the use of various cytotoxic drugs in 
combination with RAdwtTRAIL or RAdCD40LTRAIL encouraged us to 
examine whether RAd-delivered TRAIL would positively interact with these 
drugs. 
 
5.2.4 : Drug interaction with RAd expressing wtTRAIL or CD40LTRAIL 
fusion proteins in HepG2  cells 
To determine the appropriate concentrations of drugs to be used in examination 
of the synergy between these drugs and RAd vectors expressing wtTRAIL or 
CD40LTRAIL fusion, HepG2 cells were cultured with increasing concentrations 
of different cytotoxic drugs [Cisplatin (CIS), Doxorubicin (DOX), 5 Fluorouracil 
(5FU), Sorafenib (Sor) and Paclitaxel (Pac); selected on the basis of their 
differing intracellular targets] and then plated out at a density of 10 x103 
cells/well in 96-well plates. Forty-eight hours later, cell viability was evaluated 
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by WST-1 assay.  A concentration of 10M of CIS, 0.5µM of DOX, 50µM of 5FU, 
0.5µM Sor, and 1µM of Pac were sufficient to induce approximately 50-70% cell 
viability in comparison with the untreated controls. 
To examine the interaction between TRAIL-expressing adenoviruses and the 
cytotoxic drugs at the pre-estimated working concentrations, HepG2 cells were 
infected with 20 MOI of RAdwtTRAIL, RAdCD40LTRAIL, RAdMock or left 
without infection as a negative control or treated with sTRAIL at a 
concentration of 100ng/ml. Cells were then plated out at a density of 10x103 
cells/well in 96-well plates. Twenty-four hours post-infection cells were either 
cultured with the different drugs or left without treatment for a further 24 
hours. Cell viability was assessed by WST-1 assay. Results showed that RAd 
expressing CD40LTRAIL but not RAdwtTRAIL does interact significantly with 
Sorafenib and to a limited extent with 5FU, and DOX. However, no interaction 
with Pac was detected (Figure 5.3).  However, no positive interaction between 
sTRAIL and drugs was observed. 
.  
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Figure 5.3: Drug interaction with TRAIL in HepG2 cells.  
HepG2 cells were infected with 20 MOI of RAdwtTRAIL (AdL), 
RAdCD40LTRAIL (AdncL), RAdMock (AdM) or left without infection as a 
negative control or treated with 100ng/ml of sTRAIL for 24 hour then either 
cultured with 10M of Cisplatin, 0.5µM of Doxrubicin, 50µM of 5FU, 0.5µM 
Sorafenib, and 1µM of Paclitaxel or left without treatment for another 24 hours. 
Cell viability assay was then assessed using the WST-1 assay. Results are mean 
of triplet samples ±SD. 
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5.2.5 : Drug interaction with RAd expressing wtTRAIL or CD40LTRAIL 
fusion proteins in OVCAR-3 cells 
To determine the appropriate concentrations of drugs to be used to study the 
interaction with TRAIL-expressing adenoviruses, OVCAR-3 cells were cultured 
with increasing concentrations of different cytotoxic drugs [Cisplatin (CIS), 
Doxorubicin (DOX), 5 Fluorouracil (5FU), Sorafenib (Sor) and Paclitaxel (Pac) 
then plated out at a density of 15 x103 cells/well in 96-well plates for estimating 
the dose response. Forty-eight hours later, cell viability was evaluated by WST-
1 assay.  Results obtained showed that a concentration of 10M of CIS, 0.5µM of 
DOX, 50µM of 5FU, 0.5µM Sor, and 1µM of Pac induced approximately 60-70% 
cell viability in comparison with the untreated controls. Therefore, OVCAR-3 
cells were infected with 10 MOI of RAdwtTRAIL, RAdCD40LTRAIL, RAdMock 
or left uninfected as a control or treated with 100ng/ml sTRAIL. Twenty-four 
hours post-infection cells were either treated with the drugs at the above 
mentioned concentrations or left without treatment for a further 24 hours. Cell 
viability was assessed by WST-1 assay. As shown in figure 5.4, RAd expressing 
wtTRAIL or CD40LTRAIL fusion sensitized OVCAR-3 cells to Sorafenib with 
greater sensitivity observed in RAdCD40LTRAIL-infected cells, also some 
positive interaction between RAd expressing either wtTRAIL or CD40lTRAIL 
were noticed with 5FU, where lower  degree of sensitivity were detected as well 
with sTRAIL-treated cells.   
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Figure 5.4: Drug interaction with TRAIL in OVCAR-3 cells.  
OVCAR-3 cells were infected with 10 MOI of RAdwtTRAIL (AdL), 
RAdCD40LTRAIL (AdncL), RAdMock (AdM) or left without infection as a 
negative control or treated with 100ng/ml of sTRAIL for 24 hour then either 
cultured with 10M of Cisplatin, 0.5µM of Doxrubicin, 50µM of 5FU, 0.5µM 
Sorafenib, and 1µM of Paclitaxel or left without treatment for another 24 hours. 
Cell viability assay was then assessed using the WST-1 assay. Results are mean 
of triplet samples ±SD. 
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direct effect or RAdCD40LTRAIL on cell viability compared to RAdwtTRAIL or 
RAdMock viruses. Giving that blocking of the cleavage of TRAIL from cell 
surface in RAdwtTRAIL-infected cells using the MMPI II inhibitor clearly 
demonstrated the potential effect of membrane-bound TRAIL in cell death 
induction and apoptosis in TRAIL receptors positive cells. Indeed  
RAdCD40LTRAIL was also more potent in cell viability reduction than either 
RAdwtTRAIL or the sTRAIL as RAdCD40LTRAIL exhibited more cell viability 
reduction compared to other forms of TRAIL. 
RAdwtTRAIL or RAdCD40LTRAIL-induced cell viability reduction could be 
attributed to apoptotic cell death induction as evidenced with higher caspases 
3/7 activity. In line with the observed levels of cell viability reduction induced 
either by RAdwtTRAIL or RAdCD40LTRAIL, higher levels of caspases 3/7 
activity was detected in RAdCD40LTRAIL-infected cells compared to 
RAdwtTRAIL-infected cells, where no caspases 3/7 activity was detected in 
uninfected or sTRAIL-treated control cells.  
The finding that sorafenib sensitizes TRAIL receptors-positive carcinomas to  
RAd expressing either wild type TRAIL or non-cleavable CD40LTRAIL fusion 
than other drugs used in this study might be related to the ability of Sorafenib 
to down-regulate FLIP protein expression. Sorafenib has been reported to 
enhance TRAIL-induced cell death via down-regulation of FLIP protein (Liobet 
et al., 2010), However, there are several other possible explanations. For 
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example, there may be an additive growth inhibitory effect of Sorafenib due to 
its ability to induce caspases-independent cell death (Katz et al., 2009). 
Alternatively, drugs may influence the downstream signalling pathways that 
mediate TRAIL-induced cell death. 
In order to fully elucidate the interactions between TRAIL and conventional 
chemotherapy further studies are required. 
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6.1 : Summary and future work. 
The results presented in this thesis describe the generation of replication- 
deficient adenoviruses expressing either wild-type TRAIL or a membrane 
bound CD40LTRAIL fusion. The expression of TRAIL proteins have been 
confirmed by western blotting analysis. We hypothesized that RAd-delivered 
TRAIL provides more sustained stimulus to the TRAIL receptors by the virtue 
of the expression at the cell membrane. Furthermore, the ability of RAd 
wtTRAIL to induce cell death in TRAIL receptor 1 and  2 positive carcinoma 
was found to be enhanced by inhibition of matrix metalloproteinases (MMP) 
activity, a further indication of that membrane–bound TRAIL is more potent in 
inducing cell death than the wtTRAIL and sTRAIL. Therefore an attempt to 
identify the TRAIL cleavage site was made, given that TRAIL possesses high 
sequence homology between FasL and CD40L, sequence alignment between 
CD40L, FasL and TRAIL identified a possible cleavage site in the TRAIL 
sequence 105EKQQ108. Therefore we generated a couple of TRAIL mutants with 
the identified sequence and with further sequence deletion spanning the 
105EKQQHISPLV115 motif. However these deletions failed to block the cleavage 
of TRAIL from membrane in pShuttle TRAIL mutant 1 or 2 (mt1 or mt2)-
transfected HEK293 cells and sTRAIL was still detected in those cells as 
confirmed by sTRAIL ELISA assessment. This could be as a result of not 
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targeting the right cleavage site or that MMP cleaves TRAIL at multiple 
cleavage sites. 
The fact that both CD40L and TRAIL belong to the same family and share a 
significant homology (25-30%) and that we have successfully mutated the 
CD40L cleavage site stimulated the idea of making a hybrid fusion between 
CD40L and TRAIL. Therefore, we generated an adenovirus vector that 
expresses the CD40LTRAIL fusion. The expression of the CD40LTRAIL fusion 
from the RAdCD40LTRAIL virus was confirmed by western blotting analysis. 
The results showed that CD40LTRAIL protein expressed from 
RAdCD40LTRAIL is not susceptible to cleavage from membrane by the action 
of the MMPs since RAdCD40LTRAIL-infected cells failed to release any soluble 
TRAIL into the culture medium compared with RAd expressing wild-type 
TRAIL. Furthermore the RAdCD40LTRAIL was more potent in reducing cell 
viability than either RAdwtTRAIL or the sTRAIL. 
We further observed that RAdwtTRAIL or RAdCD40LTRAIL-induced cell 
viability reduction is due to apoptosis as evidenced by higher caspases 3/7 
activity. 
The adenovirus vectors used to deliver TRAIL in these studies have been 
rendered replication deficient by virtue of deletion of E1 and E3 viral genes. It is 
increasingly recognised that such vectors provide inefficient gene delivery in 
patients and that this may be enhanced through the use of selectively 
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replicating adenoviruses, which are capable of replication in tumour cells but 
not normal cells in order to amplify transgene expression and, further, to 
contribute viral oncolysis. Thus, the generation of a replication-competent 
adenovirus expressing the membrane bound CD40LTRAIL fusion should most 
likely have significantly greater cytotoxic effects than those obtained with 
replication-deficient CD40LTRAIL expressing adenovirus through greater 
CD40LTRAIL expression as well as viral oncolysis. This would also result in 
membrane bound CD40LTRAIL being expressed within the tumour cell 
environment enabling an autocrine/paracrine ‘bystander’ activation of TRAIL 
receptors. A further advantage of such a vector is that the conditional viral 
replication provides an additional level of tumour specificity. 
Previous studies have shown that phosphorylated JNK and P38 are 
downstream pathways that contribute to the TRAIL-induced cell death in 
TRAIL-receptor positive carcinomas, dissecting these pathways may reveal the 
importance of usage of the specific inhibitors that can block these pathways to 
enhance RAdCD40LTRAIL-induced cell death, highlighting the importance of 
such strategy in the treatment of cancer in the future that may allow selection of 
combination of small molecule inhibitors with sTRAIL or anti TRAIL mAb that 
can induce same signals as membrane bound TRAIL without problems of gene 
therapy. 
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In this thesis, we also report that sorafenib sensitizes TRAIL receptors-positive 
carcinomas to RAd expressing either wild type TRAIL or non-cleavable 
CD40LTRAIL fusion to a greater extent than other chemotherapeutics drugs 
used in this study. This sensitization could be due to the ability of Sorafenib to 
down-regulate FLIP protein expression (Liobet et al., 2010). In order to fully 
elucidate the interactions between TRAIL and conventional chemotherapy 
further studies are required. The time between treatment of chemotherapy and 
TRAIL are important. Start the treatment with TRAIL then chemotherapy could 
have more potent effect in cell death. Again, it is important in our future studies 
to examine the effects of this combination on the expression of death receptor, 
pro-apoptotic and pro-survival protein expression. The effects of TRAIL and 
chemotherapy on the ability of stimulate anticancer immune responses and 
possible anti-angiogenic effect requisite further studies. 
The advantage of patients using adenovirus gene therapy is sustained 
expression of membrane bound TRAIL that are potent in cell death induction. 
On the basis of the sound data presented in this thesis, we propose adenovirus 
delivered CD40LTRAIL fusion to be highly interesting for further study as a 
novel anti-cancer agent. 
The challenges of using adenovirus vectors are highly immunogenic and 
activate both innate and adaptive immune response; the non-specific immune 
responses have an inhibitory effect on gene expression. In addition, if the 
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adenovirus cannot replicate in tumour cells it need inject repeatedly with the 
same recombinant vectors. However, re-injection of the same vectors may not 
be effective because induction of host immune response. On the basis of these 
challenges further studies on recombinant adenovirus virus used for gene 
therapy are required. 
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